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RIASSUNTO 
Lo scopo principale della terapia immunosoppressiva dopo trapianto di fegato è 
passato dalla prevenzione del rigetto acuto alla preservazione della funzionalità a 
lungo termine dell’organo trapiantato e alla prevenzione degli effetti collaterali 
dovuti alla terapia immunosoppressiva. Per perseguire tale scopo è necessaria 
una gestione ottimale della terapia immunosoppresiva stessa. Tuttavia, la 
misurazione dei livelli ematici dei farmaci immunosoppressori, generalmente 
utilizzati come surrogato dei livelli di immunosoppressione, non fornisce 
informazioni relative alla reale intensità della soppressione del sistema 
immunitario. Pertanto l’individuazione di marcatori biologici di rigetto acuto e/o di 
tolleranza risulta fondamentale per poter migliorare la gestione della terapia 
immunosoppressiva dopo-trapianto di fegato.  
Gli scopi degli studi riportati in questa tesi sono: 1) determinare l’incidenza e gli 
eventuali fattori di rischio di rigetto acuto dopo trapianto di fegato, valutare in che 
l’influenza del rigetto acuto e della sua severità istologica sulla sopravvivenza 
dell’organo e del paziente dopo trapianto di fegato; 2) valutare il ruolo degli indici 
di funzionalità epatica e della conta eosinofilica ematica come potenziali 
marcatori biologici di rigetto acuto dopo trapianto di fegato, in particolare di grado 
moderato/severo; 3) valutare, prima e dopo trapianto di fegato l’espressione di 
specifici marcatori immunologici di rigetto acuto.  
I risultati degli studi condotti hanno evidenziato come pazienti con diagnosi di 
rigetto acuto alla biopsia di protocollo presentino una sopravvivenza di organo e 
paziente, a 1, 5 e 10 anni dal trapianto di fegato, del tutto sovrapponibile a quella 
di pazienti senza evidenza istologica di rigetto acuto alla biopsia di protocollo. 
L’insorgenza di rigetto acuto di grado moderato/severo non sottoposto a 
trattamento farmacologico è tuttavia associata ad aumentata incidenza di 
decesso o perdita dell’organo post-trapianto.  
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Nel valutare potenziali marcatori biologici di rigetto acuto, abbiamo dimostrato 
che nonostante la conta eosinofilica periferica non sia sufficientemente predittiva 
per lo sviluppo di rigetto acuto post-trapianto, la differenza nella conta eosinofilica 
tra la prima e la seconda biopsia epatica può essere considerato un fattore 
predittivo di miglioramento istologico, indipendentemente dall’utilizzo o meno di 
terapia con boli steroidei. Non è stata invece evidenziata alcuna associazione tra 
l’alterazione degli indici di funzionalità epatica e l’insorgenza di rigetto acuto.  
Infine, è stato dimostrato che l’insorgenza di rigetto acuto risulta associata ad 
aumentata espressione di CD28 e CD38 sia sui linfociti T CD4+ che CD8+ e ad 
un aumento dei livelli di IL-17. Tali alterazioni del sistema immunitario potrebbero 
essere utilizzate nella pratica clinica per valutare lo stato di soppressione del 
sistema immunitario in pazienti sottoposti a trapianto di fegato con il fine ultimo di 
una gestione ottimale e personalizzata della terapia immunooppressiva. 
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SUMMARY 
In recent years, the main end point of immunosuppressive therapy after liver 
transplantation has moved from the prevention of acute cellular rejection (ACR) 
toward the preservation of long-term graft function and prevention of 
immunosuppression-related side effects. This approach requires an optimal 
management of immunosuppressive therapy according to patient risk factors.  
However, the concentration of immunosuppressive drugs in the serum of 
patients, which is generally used as a surrogate for the level of 
immunosuppression, does not provide information about the magnitude of 
suppression of the immune system. Therefore a reliable marker for the 
development of ACR, or to predict patients who could tolerate reduced 
immunosuppression, would be crucial for improving post-transplant management 
of liver transplanted patients. 
The aims of the studies presented in this thesis were: 1) to assess the incidence 
of ACR after liver transplantation, to identify potential risk factors for ACR, and to 
evaluate the impact of ACR and its histological severity on outcomes; 2) to 
evaluate the role of liver function tests and blood eosinophil count as potential 
biomarkers for ACR after liver transplantation, with special attention on prediction 
of histologically proven moderate and severe ACR; 3) to evaluate the expression 
of specific immunological markers for ACR in patients before and after liver 
transplantation.  
The results of the studies showed that patient and graft survival at 1, 5 and 10 
years after liver transplantation were not different with respect to presence or 
absence of ACR. Only untreated moderate/severe ACR was associated with 
increased death/graft loss using adjusted Cox regression analysis, whereas mild 
ACR, whether treated or not, had no effect.  
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With regards to the evaluation of potential markers of ACR, despite peripheral 
eosinophilia was not sufficiently predictive of moderate/severe ACR, the delta in 
eosinophil count between the first and second biopsies was the only independent 
predictor of histological improvement, irrespective of whether bolus steroids were 
used.  
Lastly, we demonstrated that the increased expression of C28 and C38 on both 
CD4+ and CD8+ T cells and the increased levels of IL-17. These alterations of 
immune system could be used routinely in clinical practice to assess the immune 
status of liver transplanted patients and to properly manage immunosuppressive 
therapy. 
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1. GENERAL INTRODUCTION 
 
 
1.1 Acute cellular rejection after liver transplantation 
Acute cellular rejection (ACR) was defined in 1995, as “inflammation of the 
allograft elicited by genetic disparity between the donor and recipient, primarily 
affecting interlobular bile ducts and vascular endothelia, including portal veins 
and hepatic venules and occasionally the hepatic artery and its branches” [1]. 
Viewed from a biological perspective, the recipient’s immune system is activated 
after transplantation but, because of the baseline immunosuppressive therapy, 
only some recipients will have clinical manifestations of this. An important 
distinction has to be made between histological changes of ACR, which may be 
seen in the absence of any significant clinical or biochemical abnormalities 
(biological rejection), and those accompanied by clinical signs of graft dysfunction 
(clinical rejection). Abnormalities of liver function tests are almost universally 
present, and symptoms absent, so in clinical practice, in the vast majority of the 
cases, the distinction between clinical and biological rejection can rarely be 
made. 
Most cases occur in the early postoperative period within 30 days, whereas late 
cases are usually associated with non-adherence to immunosuppressive therapy. 
However incidence varies according to whether ACR is defined on the basis of 
clinically significant ACR or simply on the basis of histological abnormalities or a 
combination of the two. Clinically significant ACR occurs in approximately 50% of 
patients, whereas histological abnormalities can be seen in up to 80% of protocol 
biopsies performed at the end of the first week following transplantation [2]. 
The three main histopathological features are: 1) a predominantly mononuclear, 
but mixed portal inflammation, containing blast-like or activated lymphocytes, 
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neutrophils and eosinophils; 2) subendothelial inflammation of portal or terminal 
hepatic veins (or both); 3) bile duct inflammation and damage (Figure 1.1). 
In general, at least two of the above histopathological findings, and biochemical 
evidence of liver damage, constitute the minimal diagnostic criteria for hepatic 
ACR. The diagnosis is strengthened if >50% of the ducts are damaged or if 
unequivocal endothelitis of the portal vein branches or terminal hepatic venules 
can be identified (Table 1.1). 
 Early studies of the ACR were focused mainly on inflammatory changes 
occurring in portal tracts, but also recognized the presence of inflammation 
involving hepatic venous endothelium and surrounding liver parenchyma [3-5]. 
During the 8th Banff Conference on Allograft Pathology in 2005, the term central 
perivenulitis emerged to describe a spectrum of inflammatory regions of the liver 
that are in most cases thought to be a manifestation of liver ACR. In cases in 
which perivenular inflammation occurs within the first weeks of liver 
transplantation and is associated with characteristic portal tract changes, the 
diagnosis of rejection is straightforward [6]. However in cases where portal 
inflammation lacks typical features of ACR the term isolated central perivenulitis 
should be used [7]. Krasinkas et al. [7] demonstrated that isolated central 
perivenulitis is a common finding in late post-transplant biopsies and that most 
cases are probably related to rejection and are associated with a worse outcome 
compared to cases of purely portal-based rejection. In 2004 Lovell et al. [8] found 
that patients with centrilobular alterations in their first post-transplant biopsy 
(n=15) developed more frequently ACR (60% vs. 30%; p<0.04) and subsequent 
episodes of chronic rejection (53% vs. 25%; p<0.04) when compared to patients, 
who did not have centrilobular alterations (n=20).  
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In 1997, an international consensus on a common grading system for ACR was 
achieved and subsequently it has been prospectively tested and proved to be 
simple, reliable, and clinically relevant [9-11].  
According to this Banff schema, which represents a merger and simplification of 
many previously published studies, there are two main components: the first is a 
global assessment of the overall ACR grade (indeterminate, mild, moderate, 
severe), the second involves scoring the three specific features of ACR semi-
quantitatively to produce an overall Rejection Activity Index (RAI) [12]. 
 
 
1.1.1 Immunological basis of acute cellular rejection 
 
1.1.1.1 Mechanisms of acute cellular rejection 
After liver transplantation, ACR is initiated by the large number of recipient T cells 
that recognize donor alloantigens [13, 14]. Donor alloantigens are processed by 
specialized antigen-presenting cells (APCs), with donor MHC molecules which 
are internalized by donor and recipient APCs and MHC peptide fragments 
presented to the recipient’s T cells. Antigen presentation involves engagement of 
these peptide antigenic fragments within a groove on the MHC molecules of the 
APC surface.  
Three non mutually exclusive pathways of allorecognition have been described. 
In the direct pathway, recipient T cells recognize intact allogeneic MHC 
molecules on the surface of donor APCs. This pathway is responsible for the 
large proportion of T cells that have reactivity against alloantigens due to cross-
reactivity of the T-cell receptor (TCR) with self and foreign MHC molecules. In the 
indirect pathway, recipient APCs trafficking through the allograft phagocytose 
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allogeneic material shed by donor cells and present it to recipient T cells on 
recipient MHC molecules. Lastly in the semidirect pathway, recipient APCs 
acquire intact MHC molecules following direct contact with donor APCs and/or 
through fusion with donor APC-derived exosomes. These chimeric recipient 
APCs stimulate recipient T cells through direct and indirect pathways [15]. 
Although the ACR response is mediated primarily by CD4+ T cells C, many 
activated CD8+ T cells infiltrate the transplant at the time of rejection [16], along 
with other mononuclear leukocytes. Cells of the innate immune system, such as 
natural killer (NK) cells, are also present in allografts during rejection. NK cells 
can recognize alloantigens because they constitutively express inhibitory 
receptors that are specific for self- MHC class I antigens [17]. 
 
1.1.1.2 Role of inflammation in T-Cell commitment  
Newly engrafted organs are subject to intense inflammation. The accrued injury 
to the transplant, caused organ procurement, cold preservation, surgical trauma, 
and reperfusion injury, leads to the release of proinflammatory cytokines such as 
IL-6, TNFα, and IL-1β. The characteristics of the inflammatory environment in 
which donor-reactive CD4+ T cells recognize donor antigens seems to play a 
crucial role in determining the commitment of these cells. Thus, depending on the 
cytokines present when antigen activation occurs, naïve CD4- helper T cells can 
acquire a variety of cytopathic and/or immunoregulatory phenotypes [18]. CD4+ T 
cells activated in the presence of IL-12 become interferon γ–producing Th1 cells 
with tissue-destructive properties, whereas CD4+ T cells activated in the 
presence of IL-4 differentiate into Th2 cells. In the absence of pro-inflammatory 
cytokines, TGF-β induces expression of Foxp3 and differentiation of CD4+ T cells 
into Tregs. In contrast, expression of TGF-β with IL-6 or IL-21 prevents 
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development of Tregs, leading activated CD4+ T cells to become cytopathic Th17 
cells [18-21]. 
It was believed that antigen-activated helper T cells became terminally 
differentiated Th1 or Th2 cells with opposite effects: Th1-dependent cytopathic 
rejection or Th2-dependent cytoprotective effect. However Th1 and Th2 can each 
mediate graft rejection [22, 23], whereas Treg cells are the key inhibitors of 
cytopathic, allospecific immune responses [24-26]. Moreover it has been recently 
shown that Th17 and Tregs have a significant plasticity and are closely 
interlinked [27]. Thus, Tregs can differentiate into IL-17–producing cells in the 
presence of IL-2 and IL-1β [28], whereas in the presence of IL-27, Th17-
producing cells also produce IL-10, an immunosuppressive cytokine that 
prevents them from functioning as destructive effector cells [29]. 
Therefore the current paradigm is that the development of graft rejection or 
acceptance, is determined by the balance between Th1 and Th17 CD4+ T cells 
versus Treg cells, with the level of inflammation being crucial in the 
microenvironment in which T-cell activation takes place.  
 
1.1.1.2 Memory T-Cell and graft acceptance 
Upon re-exposure to donor antigen, donor-reactive memory cells respond faster 
and more powerfully than naive T cells, producing cytolytic effects on the 
transplanted tissue [30, 31]. Memory T cells can be divided into “central” and 
“effector” cells [32]. Central memory T cells recirculate through the spleen and 
lymph nodes, and are responsible for recall antigen responses, whereas effector 
memory T cells are excluded from lymphoid tissues, migrating to peripheral 
tissues where they exert rapid and potent effector functions [32]. Due to the 
 
6 
continuous exposure to foreign antigens, memory T cells represent 
approximately 50% of the total T-cell pool in adults. 
Patients who have not received a transplanted organ can still generate donor-
reactive T cells, through immunization by direct exposure to alloantigens via 
pregnancy or blood transfusion [33]. Furthermore, donor-reactive memory T cells 
can be generated in the absence of alloantigen exposure, through heterologous 
immunity, wherein an antigen-specific immune response affects the response to 
an unrelated antigen through cross-reactivity of the T-cell receptor [34]. Some 
memory T cells are therefore primed by an antigenic pathogen-derived peptide 
and cross-react with allogeneic (often MHC-derived) peptides presented by self 
or donor MHC molecules. Following transplantation, alloreactive naïve T cells 
can acquire a memory phenotype and generate a substantial pool of donor-
reactive memory T cells, even when the recipient is under immunosuppressive 
therapy.  
Because of their capacity to rapidly generate effector immune responses, 
memory T cells appear to be particularly efficient at mediating allograft rejection 
[35, 36]. Moreover, memory T cells are less sensitive than naïve T cells to many 
immunosuppressive strategies, such as T cell–depleting antibodies [37] or 
inhibitors of mammalian target of rapamycin [38]. Given the lower efficacy of 
conventional immunosuppressive drugs in the neutralization of previously 
activated or memory lymphocytes, it is not surprising that memory T cells also 
exert harmful effects in clinical transplantation. 
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1.1.2 Risk factors of acute cellular rejection 
Several studies have aimed to identify patients with a greater risk for developing 
ACR, but with some exceptions, they have been limited to a small number of 
patients and focused on a limited number of risk factors, and the results have 
been frequently contradictory. For this reason there is no consensus about the 
majority of factors predisposing to the occurrence of acute rejection after liver 
transplantation. 
Data from Birmingham [39, 40] show that there is a lower incidence of ACR when 
there is no evidence of immune involvement in the pathogenesis of the original 
liver disease, for example acute liver failure (ALF) from paracetamol. In contrast, 
in patients transplanted for primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC), in which immune-mediated damage of bile ducts is a feature of 
the original disease, ACR occurs more frequently and there is more frequent 
progression to ductopenic rejection. In 63 patients reported by Hayashi et al. [41] 
patients with autoimmune hepatitis had more acute rejection than patients with 
alcoholic cirrhosis (81% vs. 46.8%, p<0.001) regardless of the type of 
immunosuppression. Steroid-resistant rejection also occurred more frequently in 
patients with autoimmune (AUTO) liver disease than in patients with alcoholic 
liver disease (38.1% vs. 12.8%; p=0.003) with a trend towards more chronic 
rejection (11.1% vs. 2.1%). However, there was no difference in allograft or 
patient survival at 1 and 3 years. Berlakovich et al. [42] evaluated 252 liver 
transplanted patients: those who had undergone liver transplantation for alcoholic 
liver disease (ALD), hepatocellular carcinoma (HCC) and posthepatitic cirrhosis 
had less ACR and less need of rescue therapy than patients who had received 
liver transplantation for cholestatic disease (n=42). The cumulative rates of ACR 
episodes per patient per month at 6 months, when 94% of all ACR episodes 
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occurred, were: 0.45 for alcoholic cirrhosis, 0.55 for post-hepatitic cirrhosis, 0.65 
for HCC and 1.0 for cholestatic disease. 
The group, which has been consistently shown to have a lower incidence of 
acute and chronic rejection is chronic hepatitis B. This might reflect the 
underlying defect in cell-mediated immunity, which allowed the patients to 
become chronically infected with the virus in the first place [43, 44]. 
Farges et al. [44] in a retrospective analysis of 330 patients who were liver 
transplant recipients for chronic liver disease, found that ACR (48% at 1 year) 
and chronic rejection (10% at 3 years) were comparable in patients who had 
undergone liver transplantation for PBC, PSC, AUTO and HCV. However, the 
incidence of ACR (but not chronic rejection) was significantly lower in patients 
who had undergone liver transplantation for ALD (29% at 1 year), or hepatitis B 
virus (HBV) cirrhosis (21% at 1 year) and the latter also had lower chronic 
rejection (0% at 3 years). Thus some groups of patients can receive less 
immunosuppresion. In particular as HBV replication is potentiated by 
immunosuppression, it is also beneficial to reduce immunosuppression in these 
patients. However, Wiesner et al. [11], using multivariate analysis, showed that 
the 6-week incidence of ACR in a cohort of 762 consecutive adult liver transplant 
recipients was not dependent on the underlying disease. 
Neuberger et al. [40] showed that the percentage of patient with severe ACR at 
the liver biopsy performed 7 days after the transplantation was higher among 
patients transplanted for HCV-related liver disease (69%) compared to other 
aetiologies. 
Although it is difficult to draw firm recommendations from these studies, most 
centres tend to lessen maintenance immunosuppression for HBV, HCV cirrhosis, 
alcoholic liver disease and HCC and/or use early steroid withdrawal, from the 
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outset. Conversely, patients with AUTO, PBC, or PSC may need steroid 
maintenance and heavier initial immunosuppression. 
Gomez-Manero et al. [45] reviewed 133 transplanted recipients to identify 
predisposing factors for early (≤45 days after liver transplantation) ACR. No 
protocol liver biopsies were performed. Younger recipients, those with better 
hepatocellular liver function (Child-Pugh A) and those who underwent 
transplantation for liver disease other than ALD, had a greater risk for early ACR. 
Combining these three variables, they developed a mathematical model to allow 
prediction of the individual risk of each patient.  
 
 
1.1.3 Prognostic factors of acute cellular rejection 
 
1.1.3.1 Histological severity 
McVicar et al. [46] described a group of patients who had focal rejection in the 
hepatic allograft biopsy defined as lymphocytic infiltration involving less than 20% 
of portal tracts. In the follow up of patients showing focal or mild rejection, only 
six (15%) patients subsequently developed abnormal liver function tests and 
required treatment with additional immunosuppression for ACR [47], suggesting 
additional immunosuppression is not needed in these patients, and close follow-
up would identify the small number requiring therapy. 
In Birmingham, during follow up of 151 patients to assess the effect of not 
treating mild ACR (protocol 7-day biopsies), 97 had histologically mild rejection: 
50 had biochemical dysfunction and received prednisone for 3 days, while the 
remaining 47 cases with stable biochemistry had no additional treatment. Fifty-
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four patients with no ACR were included for comparison. The outcome at 3 
months in all three groups was similar [2]. 
Wiesner et al. [11], in a cohort study of 762 consecutive adult liver transplant 
recipients, examined the association of histological severity of ACR and overall 
patient outcome. Using univariate analysis, ACR overall, including mostly the 
milder grades, was significantly associated with an increased patient survival (RR 
0.71, p=0.05) and a trend toward improved graft survival. Moreover, adjusting for 
other risk factors such as age and renal insufficiency revealed no significant 
decrease in survival among patients who had ACR. These findings were similar 
to those of Fisher et al. [48], who analysed nine studies (comprising a total of 
1473 patients), and found that there was no correlation between mortality and 
incidence of treated ACR.  
These findings in liver transplantation are in contrast to renal transplantation in 
which acute rejection is significantly associated with decreased patient and graft 
survival. Why ACR in liver transplant recipients is not associated with decreased 
patient and graft survival remains unexplained. It is possible that ACR in the 
setting of controlled alloreactivity exerts a tolerizing effect, making the graft less 
susceptible to further immunological attack. However, it should be noted that 
successful treatment for ACR occurs in nearly all cases. Thus the correct 
interpretation of the finding reported above is that the occurrence and successful 
treatment of ACR does not influence survival in liver transplant patients, but it 
does imply that abolishing early ACR need not, and indeed, should not be a goal 
of initial immunosuppression.  
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1.1.3.2 Timing 
As regards timing of ACR, there is no firm consensus to define what is early or 
late rejection. In three different studies the timing and the outcome varied 
according to the definition of each centre. 
In a retrospective multicentre analysis of 623 liver transplants, the cumulative 
incidence of biopsy proved ACR was 59% for early episodes (<6 months) and 
21% for late episodes (≥6 months). Patient and graft survival did not differ 
significantly between those who experienced an early ACR episode and those 
who did not (p=0.49 and p=0.13, respectively). Furthermore, these parameters 
did not differ significantly between recipients who experienced a late ACR 
episode and those who did not (patient survival p=0.18 and graft survival p=0.20) 
(57). 
Wiesner et al. [11] analysed 762 consecutive adult liver transplant recipients and 
found 367 (48%) who developed at least one ACR episode within the first 6 
weeks post-transplantation. Multivariate analysis indicated that ACR was not 
significantly associated with mortality but there was a trend to better survival (RR 
0.78, p=0.25) and re-transplantation free survival (RR 0.86, p=0.44). However, 
severe ACR doubled the risk of death or re-transplantation compared to mild 
ACR. Using proportional hazards modelling, in the same study, seven factors 
were identified as independently associated with an increased incidence of early 
ACR: younger recipient age, lack of renal impairment, lack of oedema, higher 
AST levels, fewer human leukocyte antigen DR matches, longer cold ischemic 
times and older donors. 
Mor et al. [49] retrospectively reviewed 375 liver transplants, and defined late 
onset ACR as that which occurred after 6 months. There were 315 episodes of 
early ACR in 226 patients, and 31 episodes of late ACR in 26 patients. Low 
 
12 
cyclosporine (CsA) levels appeared to account for 58% of these late episodes. 
Most episodes of rejection responded to pulse corticosteroids, and chronic 
ductopenic rejection arose in only two patients. There was no difference in 
survival between patients experiencing early and late ACR. 
Anand et al. [50] reviewed late onset ACR, defining it as rejection recognized 
after the first 30 days post-transplantation. They evaluated 717 patients who had 
undergone transplantation in Birmingham between 1982 and 1994: 59 (8%) 
patients had 71 episodes of late ACR. They too found that the most common 
precipitating event was low levels of calcineurin antagonists, and that most acute 
episodes of ACR in this timeframe were responsive to standard therapy. 
However, in contrast to Mor et al. [49], Anand found that 16 (27%) of 59 patients 
developing late onset ACR progressed to chronic ductopenic rejection and graft 
loss. Delayed response to an earlier episode of ACR, and centrilobular necrosis 
or bile duct loss at the time of diagnosis of late ACR, were associated with high 
risk of progression to chronic rejection and graft loss. 
 
1.1.3.3 Number of episodes 
In an abstract, Wiesner et al. [51] showed that the number of episodes of ACR 
and the histological severity were significantly associated with chronic rejection 
(p<0.001). Dousset et al. [52] prospectively evaluated 170 liver transplanted 
patients and showed that there was no difference in graft function between 
patients with a single episode of ACR (n=56) and those without ACR (n=84). 
Among patients treated for a single episode of ACR, late hepatic function was not 
influenced by the severity of ACR, nor by the response to corticosteroids. In 
contrast, patients with more than one ACR episode (n=30) had significant 
impairment of liver function tests (aspartate aminotransferase, AST p<0.05; 
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alanine aminotransferase, ALT, p<0.001; alkaline phosphatase, ALP p<0.01, 
lower dye clearances (p<0.01), and more severe histological damage (p<0.001). 
The authors concluded that a single episode of ACR does not impair long-term 
hepatic function, whereas recurrent episodes can lead to damage to the liver 
allograft. 
 
 
1.2. Immunosuppressive therapy and liver transplantation 
 
1.2.1 Role of immunosuppression in liver transplantation 
The introduction of calcineurin inhibitors (CNIs) in the 1980s substantially 
reduced ACR and improved rates of early engraftment [53], however, in the last 
20 years, therapeutic regimens have not substantially evolved. 
Immunosuppressive drugs are combined to achieve potent and safe effects in the 
immediate post-transplant period, with a gradual decrease of the dose thereafter. 
In the early post-transplant period immunosuppression protocols usually include 
a CNI, azathioprine (AZA) or mycophenolate mofetil (MMF), and corticosteroids. 
The maintenance therapy is based on the same combination, but with lower dose 
and with or without discontinuation of corticosteroids. Short-term induction 
therapy, with monoclonal antibodies, is often added to the protocol, especially in 
patients with pre-transplant renal dysfunction.  
In recent years, the main end point of immunosuppressive therapy has shifted 
from the prevention of ACR toward the preservation of long-term graft function 
and prevention of immunosuppression-related side effects. 
The complete suppression of early ACR in clinical practice is no longer a goal of 
initial immunosuppression, as it may eliminate the immunological opportunity to 
provide some tolerance to the graft [40] although paradoxically clinical trials still 
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have ACR as an endpoint. At the same time, long-term outcomes of patients is 
becoming the main concern for clinicians, as the long-term side effects of 
immunosuppressive therapy cause significant morbidity and mortality. These can 
be due to direct drug toxicity such as renal dysfunction, hypertension, induction of 
diabetes and dyslipidaemias or a consequence of the immunosuppressive effect 
on the immune system such as opportunistic infections, de novo malignancy [54-
57], and influence the severity of recurrent disease, such as HCV and HCC. 
Thus there has been a development of new immunosuppressive protocols using 
a combination of drugs, with different modes of actions, allowing lower doses of 
each drug, but not necessarily in practice leading to lower immunopotency. In 
addition, increasing attention has been given to the observation that some 
patients tolerate their liver graft without need for long-term immunosuppression, 
or with greatly reduced immunosuppression. 
Lastly, it is often forgotten that, liver transplant recipients are a heterogeneous 
group of individuals with different predisposing factors for the development of 
ACR and with different co-morbidities (i.e. HCV infection, pre-transplant renal 
impairment, presence of hepatocellular carcinoma), which means that a single a 
optimal and universally applicable immunosuppressive protocol is not applicable, 
but immunosuppression should be tailored on the patient’s clinical condition and 
risk of ACR.  
 
1.2.3 Immune monitoring as measure of real immunosuppressive status 
Current immunological monitoring relies heavily on clinical judgment and on 
therapeutic drug levels and does not adequately assess the functional 
immunosuppression status of liver transplanted patients. Trough levels of drugs 
are arbitrary and are more clinically relevant for preventing excessive low or high 
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blood concentrations. Therefore, the evaluation of the real immunosuppression 
state in liver transplanted patients is a major challenge, and there is a high 
interest in the development of specific immune monitoring assays that could be 
use to assess liver transplanted patients on long-term immunosuppression.  
To date, the Cylex ImmuKnow assay, is the only commercially available test, 
which quantifies the amount of adenosine triphosphate (ATP) produced by CD4+ 
T cells after in vitro stimulation by phytohemagglutinin-L, a non–donor-specific 
mitogen.  
Kawalski et al. [58] performed a meta-analysis using this assay in solid organ 
transplanted patients and showing a high correlation between infections and 
lower ranges of ATP responses and between ACR and upper ranges of ATP 
responses. However it has been shown that this assay could be more useful in 
order to assess over-immunosuppression rather than under-immunosuppression 
[59]. Moreover recent studies have supported the use of ATP assays in liver 
transplantation for distinguishing HCV recurrence from ACR [60]. Mendler et al. 
[61] demonstrated that patients transplanted for HCV-related cirrhosis have low 
ATP responses immediately after transplant and at the time of the histological 
diagnosis of HCV recurrence. Moreover, low ATP production has been correlated 
with ta more rapid development of fibrosis, possibly due to the over-
immunosuppression and a lack of virological control  [62]. 
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1.3 Biomarkers of acute cellular rejection 
 
1.3.1 Past and present biomarkers 
A perfect diagnostic biomarker for ACR should be highly sensitive and specific, 
non-invasive, and rapidly available, and although many potential biomarkers 
have been reported to have diagnostic potential, only few have been validated 
[63]. 
Rising of liver enzymes after transplantation is often the first trigger to suspect 
ACR. However, sensitivity and specificity of liver enzymes are low and these 
enzymes cannot differentiate ACR from others complications. The area under the 
ROC curve for AST, ALT, GGT, total bilirubin and conjugated bilirubin is about 
0.5. For ALP the area under the ROC curve is slightly better (0.69) but its clinical 
significance remains doubtful [64]. 
The first potential biomarkers studied were cytokines. Soluble IL-2 receptor (sIL-
2R) levels in serum are increased as early as 10 days before ACR, but CMV 
infection [65, 66], bacterial infections and cholangitis [67, 68] can also be 
responsible for this increase. Soluble TNF receptor II (sTNF-RII), and IL-10 
increase as well during ACR and during infective complications. The 
proinflammatory cytokines IFN-γ, IL-1β and IL-4 and IL-6 were not of any use 
[68]. Kita et al. [69] observed showed that an increase in  IL-6 levels during ACR 
and during infections, but without being able to distinguish between both. Plasma 
levels of IL-15 are also increased during ACR, particularly during steroid-resistant 
ACR [70]. Levels of TNFα and of β2 microglobulin were found to be increased in 
patients with ACR, but these markers could not differentiate ACR from infections 
[71-74]. 
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Considering other proteins related to the inflammatory response, in two studies 
[75, 76] a rise of CD28 expression up to 6 days before ACR has been observed.  
It is well known that the infiltration of leukocytes into the allograft during ACR is 
regulated by the expression of adhesion molecules [77]. An increase of 
intercellular adhesion molecule 1 (ICAM-1) and E-selectin in serum was 
observed in relation to ACR. However, E-selectin [78, 79] nor ICAM-1 [80] could 
differentiate ACR from an infectious episode. A differentiation was seen between 
patients with ACR and CMV infection, where ICAM-1 levels did not increase [81].  
The role of toll like receptors (TLR) was also studied with respect to ACR. 
Patients experiencing ACR had significantly higher levels of TLR4 and a greater 
capacity to produce the pro-inflammatory cytokines TNFα and IL-6 before 
transplantation but had a down regulation of the TLR4 pathway if they 
experienced ACR. In contrast there was no correlation between TLR2 levels and 
ACR [82]. 
Apoptosis is an important mechanism of cell death during ACR and this is 
mediated via Fas ligand. Increased serum levels of soluble Fas antigen has been 
detected in patients during ACR [83]. 
Several studies illustrate that blood eosinophilia could be an interesting 
biomarker for ACR [84, 85]. In one study a positive predictive value of 82% was 
found, but more interesting a negative predictive value of 86% [86]. However, the 
response was less clear in patients who received steroids and in HCV positive 
patients. 
Another potential biomarker was alpha-glutathion S-transferase (alpha-GST) and 
Pi-glutathione S-transferase (Pi-GST). GST’s are a family of multifunctional 
detoxifying enzymes implicated in the conjugation of glutathione with several 
compounds. Alpha-GST is a low molecular weight protein widely present in the 
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hepatocyte cytosol with a short half-life. Plasma values increase rapidly in case 
of ACR, but the lack of sensitivity and specificity make this marker difficult to use 
in clinical practice [87-90]. Pi-GST is an isoenzyme exclusively found in the biliary 
epithelium of the liver that was also tested but was not found to be related to 
ACR [89]. 
In a small patient series serum amyloid A protein (SAA) was significantly 
increased during the appearance of ACR [91], but it could not differentiate ACR 
from infections [67].  
 
1.3.2 Future biomarkers 
New biomarkers, especially in the fields of genomics, proteomics and 
transcritomics have been described in recent years as a result of a constant and 
progressive research in this area. 
Considering genomic studies, loci associated with increased risk of ACR [92] or 
to poor allograft survival [93] have been identified, but no data on loci associated 
with the acute event of ACR were found. 
Several proteins are involved in the complex immunological mechanisms of ACR, 
therefore the proteomic analysis seems a promising approach to identify reliable 
biomarkers of ACR. Massoud et al [94] identified more than 40 different serum 
proteins in the serum of patients experiencing ACR. Amongst these C4 and C1q 
were independent predictors of ACR, with the best diagnostic performance being 
achieved by C4. In an animal model of liver transplantation, Cheng et al. [95] 
showed that 8 proteins were down-regulated in rats with ACR. 
Considering transcriptomics Kobayashi et al [96] found that the mRNA level of 
interferon regulatory factor 1 (IRF-1) and guanylate-binding protein 2 (GBP2) in 
leucocytes, not related to T-cell mediated immune response, were upregulated in 
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patients with ACR, but only GBP2 reached the statistical significance. ACR after 
liver transplantation seems also to be associated with a rise of MicroRNA (miR)-
122 and miR-148a, starting before the rise of transaminases [97] 
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1.4 Tables and figures 
 
 
Table 1.1. Banff schema for grading of acute liver allograft rejection. *Verbal 
descriptions of mild, moderate and severe acute rejection could also be labeled 
as grades 1, 2 and 3 respectively. 
 
Overall grade* Criterion 
Indeterminate Portal inflammatory infiltrate that fails to meet the criteria for the 
diagnosis of acute rejection 
Mild Rejection infiltrate in a minority of the triads that is generally mild 
and confined within the portal spaces 
Moderate Rejection infiltrate that expands most or all of the triads 
Severe As for “moderate” but with spillover into periportal areas and 
moderate to severe perivenular inflammation that extends into the 
hepatic parenchyma and is associated with perivenular hepatocyte 
necrosis 
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Figure 1.1. The picture (HE X20) shows marked expansion of the portal tract by 
a mixed inflammatory infiltrate containing small lymphocytes with occasional 
blasts, plasma cells, neutrophils and a moderate number of eosinophils (arrow). 
The bile ducts (B) are cuffed and infiltrated by lymphocytes and show mild 
reactive changes. There is subendothelial lymphocytic infiltration involving the 
portal vein branch (endotheliitis, V). The features are conclusive for acute cellular 
rejection amounting to moderate degree. 
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2. PROJECT AIMS 
 
The aim of the first study was to evaluate a large and consecutive cohort of liver 
transplanted patients, who had protocol biopsies, to assess the incidence of 
ACR, to identify potential risk factors for ACR, and to evaluate the impact of ACR 
and its histological severity on outcomes after liver transplantation. 
 
The aim of the second study was to evaluate the role of liver function tests and 
blood eosinophil count as potential biomarkers for ACR after liver transplantation. 
We assess whether peripheral blood eosinophil count is predictive of 
histologically proven moderate and severe ACR, as well as any relationship 
between changes in blood eosinophil count and clinical course of ACR in both 
treated and untreated patients. 
 
The aim of the last study was to prospectively evaluate the immunological status 
in patients with cirrhosis and after liver transplantation, and to identify 
immunological alterations associated with ACR. The clinical goal of this project is 
to use the immune monitoring assays to properly manage immunosuppressive 
therapy, increasing immunosuppression in patients with signs of inappropriate 
high immune cell function (at risk of infections), and decreasing it in patients with 
signs of inappropriate low immune cell function (at risk or ACR).  
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3. ACUTE REJECTION AND OUTCOMES AFTER LIVER 
TRANSPLANTATION: A PROTOCOL BIOPSY EVALUATION 
 
 
3.1 Introduction 
Diagnosis of ACR is not uniform, being based sometimes on liver biopsy 
following clinical suspicion, other times simply suspected and treated. Early ACR, 
which responds to treatment, has no negative long-term effects, and may even 
be associated with a lower risk for later immunological complications [11, 47]. 
Thus the more fundamental question is how much rejection is not harmful, such 
that complete suppression of ACR need not be a primary goal in liver 
transplantation, and importantly need not be a primary endpoint in clinical 
studies. However very few studies have evaluated therapy for ACR with respect 
to clinical outcomes. 
Moreover there have only been a few studies evaluating risk factors for ACR; 
these are insufficient for evidence-based differentiated protocols for preventing 
and treating ACR [11, 39, 42, 44, 45, 48, 98]. Lastly only three studies used 
protocol liver biopsies with [11, 44, 98] patients, and no studies evaluated the 
severity of ACR, rather than just its occurrence. Furthermore, the impact of ACR 
on subsequent patient and graft outcome remains poorly defined. 
 
 
3.2 Methods 
3.2.1 Study cohort 
From October 1988, all patients undergoing liver transplantation at our centre 
have been prospectively followed with detailed information stored on a 
computerised database. Pre-transplant data include demographic variables, past 
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medical history, blood group, lifestyle, aetiology of liver disease, ascites and 
encephalopathy, pre-transplant renal support or ventilation, and laboratory data. 
Severity of liver disease at liver transplantation was defined by Child-Pugh and 
with model for end-stage liver disease (MELD) scores. Donor variables include 
sex, age at death, blood group, ABO donor/recipient group matching and 
surgeon’s assessment of donor liver appearance.  Surgical variables include cold 
and warm ischemia time, details of anastomoses, and transfusion of blood 
products and anti-fibrinolytics intraoperatively. 
The present analysis includes all patients undergoing a first liver transplant from 
October 1988 to May 2008.  Minimum follow-up was until June 2009, thus all 
patients had the potential for at least 12 months follow-up after transplantation. 
Children aged <16 years, multiorgan transplants and deaths or re-transplantation 
within three days post-transplantation were excluded. 
 
3.2.2 Immunosuppression protocols 
The basic immunosuppression policy was to use triple immunosuppression 
therapy: CsA or Tac in combination with AZA and low dose steroids, which were 
tapered and stopped between 3-6 months after transplantation. 
Immunosuppression started immediately after transplant with intravenous 
methylprednisolone (1 mg/kg/day until July 1997 or 16 mg daily thereafter, 
followed in both cases by 20 mg oral prednisolone daily once gut function was 
restored) and AZA (1mg/kg/day) in addition to either Tac (initially 0.1 mg/Kg/day 
in two divided doses) or CsA (initially 10 mg/kg/day in two divided doses). CNI 
doses were run on the lower side of the therapeutic range and adjusted 
according to serum levels, suspicion or proven infection, renal function or toxicity. 
Between October 1996 and January 1997 patients were randomised to receive 
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monotherapy with Tac versus CsA [99]. From May 1997 to April 1999 patients 
were randomised to triple therapy with either Tac or CsA [100]. Thereafter a 
patient cohort received Tac monotherapy [101]. No antilymphocyte or antibody 
induction therapy was used and no IL-2 receptor blockers were used in this 
population. 
 
3.2.3 Protocol biopsies after liver transplantation 
The first protocol liver biopsy was planned between 5 and 10 days after liver 
transplantation. However, due to operational delays some biopsies were 
performed later, and so we considered the protocol liver biopsy to be performed 
within 14 days.  
All biopsy samples were fixed in formalin and embedded in paraffin. Histological 
sections (4µm thick; 3 levels through the tissue block) were stained with 
hematoxylin and eosin, and other histochemical stains were prepared as 
required. Immunohistochemical stains were used for biliary cytokeratins and viral 
antigens as necessary.  
 
3.2.4 Diagnosis of ACR 
In this study, we only considered histologically diagnosed ACR episodes, 
whether treated or not treated. The histological criteria for ACR included the 
presence of: 1) mixed portal inflammation including “activated” lymphocytes and 
frequently eosinophils; 2) bile duct inflammation/damage; and 3) endothelitis of 
portal and/or terminal hepatic veins. The degree of ACR was classified as none, 
mild, moderate or severe using the Royal Free Hospital scoring system [102], 
which applies the same criteria as the subsequently published Banff acute 
cellular rejection activity [12], but also includes graft eosinophilia. 
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3.2.5 Treatment of ACR 
ACR episodes were treated with a 1g daily bolus intravenous methylprednisolone 
for 3 days consecutively, followed by the baseline steroid dose of 20mg/day. If 
after the first cycle of bolus methylprednisolone, clinical and histological evidence 
of persistent ACR remained (further liver biopsy was performed 2 days after the 
last bolus), a second cycle of methylprednisolone was given. If clinical and 
histological ACR persisted, OKT3 was administered intravenously (5 to 10 days 
at 5 mg/d) or ATG or ALG. 
 
3.2.6 Statistical analysis 
Patients were stratified into those with ACR (mild, moderate or severe) and those 
with normal biopsy or with other conditions present. As there were few patients 
with severe ACR, moderate and severe rejection were combined for analysis.   
Liver diseases were grouped and analysed as follows: ALF, ALD, HBV, HCV, 
PBC/PSC/AUTO, and other liver aetiologies. Patients with HCC were classified 
according to the underlying liver disease. 
Factors associated with ACR at first protocol biopsy were identified using 
univariate and multivariable logistic regression. Recipient-related variables were: 
gender, age, blood group, aetiology of liver disease, MELD score and Child-Pugh 
score, ascites, encephalopathy, pre-transplant ventilation, pre-transplant renal 
support, previous abdominal surgery, serum albumin, bilirubin, creatinine, INR 
and urea levels at the time of transplant, eosinophil levels the day before liver 
biopsy. Donor-related variables were: gender, age, blood group, donor/recipient 
ABO group matching, and organ appearance (evaluated by the transplanting 
surgeon). Liver transplant-related variables were: year of liver transplantation, 
immunosuppressive regimen at day 1 post-transplant, hepatic artery 
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anastomosis, cold ischemia time (min), reperfusion time (min), units of blood, 
cryoprecipitate, plasma and platelets received intraoperatively.  Factors 
associated with ACR univariately (p<0.10) were included in the multivariable 
logistic regression model to identify independent associations with ACR 
(backward selection process). If MELD or Child Pugh score were significant 
univariately, as well as their components, the score was used in the multivariable 
analysis, rather than the individual components. 
Follow-up was to time of first re-transplant or death, whichever occurred first, or 
up to December 2011. 
The causes of death or graft failure after first liver transplant were evaluated as 
follows: primary-non-function (PNF) or acute vascular occlusion (grouped 
together), infection, chronic rejection, multi-organ failure, recurrence of primary 
liver disease, tumour recurrence, “de novo” tumours, and other causes. 
Survival after first liver transplant was evaluated according to: presence/absence 
of ACR, histological severity of ACR and treatment/no treatment of ACR 
episodes. This was performed using the life-table method with comparisons 
between groups made by the log-rank test.  
Discrete variables are shown as percentages and continuous variables with 
Normal distribution (Kolmogorov-Smirnov test) as mean values±SD, otherwise as 
median (range). Chi-square test was used to compare discrete variables, 
Student’s t -test for continuous variables, and ANOVA analyses for comparisons 
of three groups or more. Statistically significant differences were defined by a p-
value ≤0.05. 
Factors associated with death or graft failure were identified using Cox 
proportional hazards regression models. Variables with statistically significant 
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hazard ratios in univariate analyses (p<0.1) were included in the multivariable 
analysis. 
 
 
3.3 Results 
Liver transplantation was performed in 733 patients between October 1988 and 
May 2008. Amongst these, 648 patients had a protocol liver biopsy within 14 
days after transplantation: 6 patients died within the first 3 days after 
transplantation and 79 did not undergo protocol liver biopsy. 
In the 648 liver biopsies, ACR was diagnosed in 504 (77.8%): 266 (41%) mild, 
210 (32.4%) moderate and 28 (4.3%) severe; 76 (11.7%) had a normal biopsy 
and 68 (10.5%) had other abnormal histopathological features.   
Of the 504 patients with ACR diagnosed at protocol biopsy, 266/504 (52.7%) 
received methylprednisolone: 60/266 (22.6%) with mild ACR, 180/210 (85.7%) 
with moderate ACR and 26/28 (92.9%) with severe ACR. Of the 144 patients 
without signs of rejection, 8 (7%) received methylprednisolone before a final 
diagnosis, and all 8 had other histopathological abnormalities.  
The demographic and clinical characteristics of the 648 patients with a protocol 
biopsy between day 4 to day 14 after transplant are shown in Table 1. Recipient, 
donor and transplant variables were evaluated according to the protocol biopsy 
histology. Patients with moderate/severe ACR were significantly younger (median 
48 years) compared to patients with mild ACR (51 years) and no ACR (52 years) 
(p=0.009). The diagnosis of histopathological abnormalities other than ACR was 
more frequent in patients transplanted for ALF compared to other aetiologies 
(p=0.029), whereas the moderate/severe ACR was more frequent in patients 
 
29 
transplanted for PBC/PSC/AUTO compared to other groups (p=0.029) (Table 
3.1). 
 
3.3.1 Risk factors for ACR 
Using univariate logistic regression, factors associated with a greater likelihood of 
ACR in the first 14 days were later calendar year (p=0.005), absence of ascites 
(p=0.05), absence of pre-transplant renal support (p<0.001), absence of 
encephalopathy (p=0.01), having a PSC/PBC/autoimmune aetiology (p=0.018), 
higher level of serum albumin (p=0.02), a Child-Pugh score A (p=0.001) and sub-
optimal organ appearance (p=0.01). Conversely, a high MELD score (p<0.001), a 
high blood level of urea (p=0.003), creatinine (p=0.04), bilirubin (p=0.002), and 
INR (p=0.001) and the transfusion of blood (p=0.009), or plasma (p=0.03) or 
platelets (p=0.02) during surgery were all associated with a lower risk of ACR 
(Figure 3.1A). No association was found between ACR and donor or recipient 
age or gender, cold ischemia or reperfusion time, use of cryoprecipitate 
intraoperatively, previous abdominal surgery, eosinophil level, and 
immunosuppressive regimen. 
With multivariate logistic regression, the factors associated with ACR at first 
protocol biopsy were: absence of ascites (OR 1.59, 95%CI 1.05-2.43; p=0.003), 
no requirement for renal support (OR 3.16, 95%CI 1.54-6.47; p=0.002), and a 
suboptimal organ appearance (OR 2.67, 95%CI 1.38-5.17; p=0.004), whereas a 
higher MELD score (OR per 5 MELD points 0.85, 95%CI 0.76-0.95; p=0.01) was 
associated with a lower risk of ACR (Figure 3.1B).  
In a separate multivariable logistic regression analysis the factors associated with 
moderate/severe ACR at first protocol biopsy (versus no rejection, mild rejection 
or other conditions) were female recipient sex (OR: 1.52, 95%CI 1.09-2.11; 
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p=0.014) and no requirement for pre-transplant renal support (2.28, 95%CI 1.31-
5; p=0.04), whereas a higher recipient age (OR per 10 years of age: 0.83, 95%CI 
0.971-0.97; p=0.017) and number of blood units required (OR per 5 units: 0.84, 
95%CI 0.75-0.94; p=0.002) were both associated with a lower risk of 
moderate/severe ACR (Figure 3.1C). 
 
3.3.2 ACR and survival after liver transplantation 
Over the median follow-up period of 87.5 months (range 0.3-253.4), 190 patients 
(29.3%) died and 45 (6.9%) were re-transplanted. Overall, patient and graft 
survival at 1, 3, 5 and 10 years after transplantation were 84%, 79%, 75%, 65% 
and 81%, 75%, 71%, 62% respectively.  
Patient and graft survival at 1, 3, 5 and 10 years after liver transplantation, 
according to the absence/presence of ACR at protocol biopsy, were not 
significantly different between the two groups (patient survival: 83%, 81%, 76%, 
63% vs. 84%, 78%, 75%, 66%; p=0.928; graft survival: 81%, 78%, 73%, 61% 
versus 82%, 74%, 71%, 62%; p=0.57) (Figure 3.2).  
After removing patients with other histological abnormalities from the group with 
no rejection, there was still no difference in patient (p=0.528) or graft survival 
(p=0.17).  
Stratifying patients according to severity of ACR showed that moderate/severe 
ACR was associated with greater patient and graft survival at 1, 3 5 and 10 years 
post-transplant (90%, 84%, 80%, 73% and 87%, 80%, 76%, 70% respectively) 
compared to mild ACR (80%, 73%, 70%, 61% and 77%, 69%, 66%, 56%; p=0.04 
and p=0.016 respectively). Conversely there was no difference in patient or graft 
survival between patients with no ACR or those with any degree of ACR, or 
patients with other histopathological abnormalities (Figure 3.3).  
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When treatment of ACR (yes/no) was evaluated with respect to patient and graft 
survival treatment was associated with better patient (p=0.001) and graft survival 
(p=0.006) (Figure 3.4).  
This was due solely to patients with moderate/severe ACR who underwent 
treatment compared to moderate/severe ACR untreated patients (p=0.002 and 
p=0.018 respectively). Conversely no statistical difference in patient and graft 
survival was found in patients with mild ACR whether treated or not (p=0.589 and 
p=0.988 respectively) (Figure 3.5).  
An adjusted Cox regression analysis, using variables that were independently 
associated with outcomes (year of transplantation, donor/recipient ABO blood 
group matching, and number of blood units used during surgery), showed that 
ACR overall was not significantly associated with death or graft loss, except for 
patients whose ACR was not treated (HR 1.54, 95%CI 1.09-2.17; p<0.001). 
Stratifying this group of patients according to histological severity of ACR showed 
that this was due to untreated patients with moderate/severe ACR (HR 2.29, 
95%CI 1.18-4.44; p<0.001), whereas mild ACR whether treated or not, had no 
effect on graft survival (Table 3.2). 
 
 
3.4 Discussion and conclusions 
This study evaluated the incidence ACR and risk factors for developing ACR and 
its impact on patient and graft survival, using a well documented database with 
patients undergoing protocol liver biopsies at a single Centre.  
The impact of ACR on patient and graft survival after liver transplantation has 
only been properly evaluated in one study [11], which showed that ACR did not 
influence patient survival. However we now add to these observations, as we 
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considered not only the presence/absence of ACR, but also stratified patients 
according to the histological severity of ACR. We confirm that patient and graft 
survival are not influenced by the presence or absence of ACR. Patients 
experiencing mild ACR had worse patient and graft survival compared to patients 
experiencing moderate/severe ACR (p=0.008 and p=0.006 respectively), but by 
Cox regression analysis this was not confirmed so that this difference was 
associated with other risk factors in the model.  
Importantly our study is the first to evaluate therapy for ACR and not just the 
occurrence of ACR. Untreated ACR was associated with worse graft survival 
using adjusted Cox regression analysis (HR 1.54, 95%CI 1.09-2.17; p<0.001), 
but this was solely due to patients with untreated moderate/severe ACR (HR 
2.29; 95%CI 1.18-4.44; p<0.001). Mild ACR treated or not did not influence graft 
or patient survival. Importantly moderate/severe ACR was associated with more 
chronic rejection, which was further increased in untreated patients, as a cause 
of death or graft loss (4/14 vs. 8/56; p<0.001).  
The associations of ACR in our cohort, in which we aimed at the lower end of the 
recommended CNI trough level range, confirm the observation that the liver is a 
privileged organ in terms of immunological interactions, substantially differing 
from kidney transplantation, in which even a single episode of ACR can lead to 
graft loss. Our findings, and previous ones, suggest that ACR in liver 
transplantation needs to be understood from a different perspective. Firstly, the 
complete suppression of early cellular rejection should not be not considered as 
a primary goal of initial immunosuppression, not only because ACR “per se” does 
not negatively affect graft and patient survival, but also because it may eliminate 
the immunological opportunity to provide some tolerance to the graft [103, 104]. 
Secondly, in clinical practice, less potent immunosuppressive regimens can be 
 
33 
safely used after liver transplantation, which will reduce immunosuppression-
related side effects such as infection, renal dysfunction, cardiovascular 
complications and de novo malignancies. Thirdly immunosuppressive regimens 
can be tailored individually according to the risk of developing moderate/severe 
ACR, and/or using an initial low immunopotent regimen as standard, and then 
“responding” to moderate/severe ACR if it occurs, by treating it. Thus post-
transplant protocol liver biopsies could be planned in the subgroup of patients at 
risk of moderate/severe ACR to obtain a definitive diagnosis of the severity of 
ACR, as if not treated, moderate/severe ACR may lead to a worse patient and 
graft survival. In contrast, mild ACR (which may be more frequent with low 
immunopotency regimens) does not influence patient and graft survival, whether 
treated or not. 
Therefore it becomes crucial to identify patients at risk of moderate/severe ACR. 
Although several studies have previously attempted to assess potential risk 
factors for developing ACR after liver transplantation, none stratified patients 
according to histological severity, as we have done. 
In our study, the risk of ACR, independently from its histological grade, was 
greater in patients without ascites or encephalopathy pre-transplant, and in 
recipients receiving suboptimal organs. On the other hand patients with MELD 
score>25 experienced a significantly lower incidence of ACR, independent from 
its histological severity. These findings demonstrate that less sick recipients are 
at greater risk of developing ACR compared to patients who are transplanted in 
worse clinical condition. The influence of liver function at the time of liver 
transplantation on ACR has previously been previously evaluated in 133 patients 
(but without protocol biopsies) [45], showing that patients with who were Child-
Pugh score A had a greater risk of ACR, within the first 45 days after liver 
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transplantation. Similarly, in our study, univariately Child-Pugh score A was a risk 
factor for ACR (OR 2.63, 95%CI 1.47-4.69; p=0.001); absence of ascites, one of 
the components of Child-Pugh score, remained significant in the multivariate 
analysis. Patients with higher MELD scores were at less risk of ACR, and this 
was confirmed in the multivariate analysis (OR per 5 MELD points 0.85, 95%CI 
0.76-0.95; p=0.01). This finding reflects clinical experience; we presume that 
sicker patients have a more depressed immunity and are less likely to reject.  
The association between the use of suboptimal organs and ACR is more difficult 
to understand. However it has been previously shown that using grafts from older 
donors is per se an independent risk factor for ACR, suggesting that non 
allogenic differences can trigger immunological reactions [105, 106]. These 
findings are important because increasingly there is a general deterioration in the 
quality of donor grafts (i.e. increased donor age, high incidence of steatosis), but 
also an increased use of donors after cardiac death in some countries. Moreover 
the number of patients transplanted for hepatocellular carcinoma is constantly 
increasing, and most of these patients are transplanted with better liver function. 
All these factors could be responsible for the increased incidence of ACR with 
more recent transplant era, which occurred in our cohort.  
Patients who were most at risk of developing moderate/severe ACR were female 
recipients, most frequently with autoimmune aetiology, (OR 1.52, 95%CI 1.08-
2.11), and patients who did not require pre-transplant renal support (OR 2.28, 
95%CI 1.31-5).  
It has been demonstrated that patients with good pre-transplant renal function 
are at greater risk of developing ACR, but no distinction was made according to 
histological severity of ACR [11]. Our confirmatory findings are important, as 
more patients are requiring renal support, particularly in centres using MELD or 
 
35 
UKELD allocation systems, and these patients are often those most at risk of 
sepsis, which in turn is increased with immunosuppression. Therefore the 
rationale behind the use of low dose immunosuppressive regimens in these 
patients, would be not only to prevent post-transplant renal dysfunction and to 
reduce the incidence of sepsis, but also because of lower risk of 
moderate/severe ACR. In addition older patients (OR per 10 year increase 0.83, 
95%CI 0.71-0.97) and those receiving a greater number of blood units during 
surgery (OR per 4 unit increase 0.84, 95%CI 0.75-0.94) were also at a lower risk 
of moderate/severe ACR. Thus easily obtained clinical factors can provide a risk 
stratification for moderate/severe ACR. 
The association between reduced incidence of moderate/severe ACR and the 
increased use of blood units is of particular interest because, to our knowledge, 
this is the first time this association has been reported in liver transplantation, 
whereas it was first recognised in kidney transplantation [107]. This phenomenon 
is known as transfusion-associated immunomodulation [108]. Transfusion of 
allogenic blood products can induce a down-regulation of immune responses, 
including decreased helper to suppressor T-lymphocyte ratio, decreased NK cell 
function, defective antigen presentation and reduction in cell mediated immunity 
[109-111]. The depression of the immune system might also be the explanation 
for the significant association between reduced incidence of moderate/severe 
ACR and older recipient age. 
 
In conclusion, the results of our study clearly show that ACR after liver 
transplantation, with the exception of untreated moderate/severe ACR, does not 
influence patient and graft survival. Moreover it confirms what is practised in 
many centres based on experience, that it is not mandatory to treat patients with 
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mild ACR, as it does not influence graft or patient survival. However attention 
needs to be focussed on patients at risk of moderate/severe ACR, as if not 
treated, this increases the rates of graft loss and death. Our findings should lead 
clinicians to consider returning to perform protocol biopsies for those at risk of 
moderate/severe ACR, and reducing immunopotency of treatment protocols in 
those at least risk (older age, worse liver and/or renal function, blood 
transfusion). A general policy of a universal and initial immunosuppressive 
regimen with low immunopetency could be used, which would be escalated only 
if moderate/severe ACR occurs (and then treated), as this would reduce 
complications of immunosuppression and maintain, if not increase, graft and 
patient survival following liver transplantation [112]. Future randomized clinical 
trials should only focus on moderate/severe ACR, and not on the overall rejection 
rate. Therefore protocol biopsies will be necessary or alternatively appropriate 
and validated non invasive methods such as biomarkers [87], should be used. 
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3.5 Tables and figures 
 
Table 3.1 Demographic and clinical characteristics of all 648 transplanted 
patients who underwent first protocol liver biopsies between 4-14 days after liver 
transplantation and according to histological severity of ACR. P-values refer to 
the comparison between different histological severity of ACR. 
 
 Total cohort 
 
n=648 (%)  
Mild ACR 
 
N=266 (%)  
Mod/Sev 
ACR 
n=238 (%) 
No ACR 
 
n=76 (%) 
p 
Male recipient   60.3  65.8  52.9 61.8 0.029 
Recipient age, years  
median (range) 
49  
(17-70) 
52  
(17-70) 
48  
(17-66) 
53  
(19-67) 0.009 
Liver disease 
  ALF 
  ALD 
  HBV 
  HCV 
  PBC/PSC/AUTO 
  Other 
 
7.7 
20.5 
10 
 24.2 
24.2 
13.3 
 
4.9 
22.9 
10.9 
27.8 
22.2 
11.3 
 
8.4 
18.9 
8.8 
19.3 
29.4 
15.1 
 
9.2 
19.7 
10.5 
32.9 
19.7 
7.9 
0.029 
Ascites, no (%) 36.1 37.2 39.1 28.9 0.26 
Encephalopathy (no) 86.2 88.6 87.3 85.5 0.011 
Ventilation (no) 94.8 96.2 95 96.1 0.017 
Renal support (no) 93.8 96.2 96.2 88.2 <0.001 
MELD, median (range) 16 (6-40) 15.2 (6-40) 15.5 (6-40) 17.2 (6-40) <0.001 
Child-Pugh 
  A 
  B 
  C 
 
 18.8 
48.6 
32.6 
 
20.7 
49.2 
30.1 
 
20.6 
52.1 
27.3 
 
11.8 
51.3 
36.8 
0.001 
Abdominal surgery (no)  87.5 89.5 84.9 84.2 0.18 
Donor gender (male)   48.5 47.4 48.3 50 0.93 
Donor age, years  
median (range) 
49  
(9-75) 
43  
(11-73) 
41  
(9-76) 
37  
(11-69) 0.38 
ABO-group matching 
  Identical 
  Compatible 
  Incompatible 
 
 88.4 
 9 
2.6 
 
91 
6 
3 
 
 88.2 
10.1 
1.7 
 
88.2 
9.2 
2.6 
0.15 
 Suboptimal organ 15.7 19.9  15.1 3.9 0.009 
Years of LT 
  2003-2008 
  1999-2002 
  1988-1998 
 
28.4 
 31 
40.6 
 
27.8 
29.3 
42.9 
 
34.9 
31.1 
34 
 
6.6 
32.9 
60.5 
<0.001 
IS regimen at day 1 
  Mono 
  Double 
  Triple 
  None 
 
43 
23 
26.7 
7.3 
 
42.8 
23.9 
26.1 
7.2 
 
46.8 
19 
27.4 
16.8 
 
32.9 
31.6 
28.9 
6.6 
0.50 
Cold ischemia time, min  
median (range) 
632  
(137-1194) 
638  
(137-1194) 
619  
(290-1043) 
637.5  
(290-1194) 0.26 
Reperfusion time, min  
median (range) 
43  
(22-106) 
44  
(23-85) 
43 
 (19-85) 
42.5  
(24-106) 0.49 
Blood products, unit (median) 
  Blood 
  Plasma 
  Platelets 
  Cryoprecipitate 
 
6 (0-68) 
6 (0-35) 
2 (0-30) 
0 (0-40) 
 
6 (0-65) 
6 (0-30) 
2 (0-30) 
0 (0-40) 
 
5 (0-58) 
4 (0-56) 
1 (0-30) 
0 (0-30) 
 
6.5 (0-50) 
6.5 (0-19) 
2 (0-25) 
0 (0-20) 
 
0.001 
0.012 
0.002 
0.19 
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Table 3.2. Univariate and multivariate Cox regression analysis for risk of death or 
graft survival after liver transplantation in 648 transplanted patients who 
underwent first protocol liver biopsies between 4-14 days after liver 
transplantation. 
 
 Unadjusted Adjusted* 
RH 95%CI p RH 95%CI p 
No ACR (reference) 
Any ACR 
 
1.09 
 
0.80-1.49 
 
0.57 
 
1.27 
 
0.85-2.09 
 
0.38 
No ACR (reference) 
Mild ACR 
Mod./Sev. ACR 
Other abnormalities 
 
1.59 
1.05 
1.55 
 
1.03-2.46 
0.67-1.66 
0.89-2.69 
0.016 
 
1.48 
1.21 
1.56 
 
0.90-2.53 
0.76-1.92 
0.89-2.75 
0.082 
No ACR (reference) 
Untreated ACR 
Treated ACR 
 
1.34 
0.89 
 
0.96-1.88 
0.63-1.26 
0.017 
 
1.54 
0.98 
 
1.09-2.17 
0.69-1.39 
<0.001 
No ACR (reference) 
Mild untreated ACR 
Mild treated ACR 
Mod./Sev. untreated ACR 
Mod./Sev. treated ACR 
Other abnormalities 
 
1.43 
1.58 
1.88 
0.95 
1.55 
 
0.91-2.27 
0.91-2.73 
1.01-3.62 
0.59-1.52 
0.89-2.69 
0.13 
 
1.50 
1.53 
2.29 
1.08 
1.56 
 
0.95-2.38 
0.88-2.65 
1.18-4.44 
0.67-1.74 
0.89-2.74 
<0.001 
*Adjusted for year of transplantation, ABO-group matching, units of blood received 
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Figure 3.1. Risk factors for the development of ACR at first protocol biopsy in 
648 patients between 4-14 days after liver transplantation. Figure 1A, 1B: 
univariate and multivariable logistic regression analysis of risk factors for ACR 
(mild/moderate/severe vs. no ACR/other abnormalities). Figure 1C: multivariable 
logistic regression analysis of risk for moderate/severe ACR (vs. no/mild 
ACR/other abnormalities). 
 
A. 
   
*per  1 unit increase; ** per 3 unit increase; °per 5 point increase; ‡per 1 point increase; §per 5 unit 
increase; ◊per 10 year increase; †per 4 unit increase; •per 60min increase 
 
 
B. 
 
*per 5 unit increase 
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C. 
 
* per 4 unit increase; ** per 10 year increase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.1 1 10
Renal support (no)
Recipient gender (female)
Recipient age**
Blood units*
Odds Ratio
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Figure 3.2. Patient (A) and graft (B) survival after liver transplantation according 
to presence/absence of acute cellular rejection at the first protocol biopsy. 
 
A. 648 patients; log-rank p=0.92 
 
 
B. 648 patients; log-rank p=0.57 
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Figure 3.3. Patient (A) and graft (B) survival after liver transplantation according 
to histological severity of acute cellular rejection at the first protocol biopsy.  
 
A. 648 patients; global log-rank p=0.04 
 
 
B. 648 patients; global log-rank p=0.016 
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Figure 3.4. Patient (A) and graft (B) survival after liver transplantation according 
treatment or no treatment of the acute cellular rejection diagnosed at the first 
protocol biopsy. 
 
A. 648 patients; log-rank p=0.001 
 
 
B. 648 patients; log-rank p=0.006 
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Figure 3.5. Survival after liver transplantation according treatment or no 
treatment of the acute cellular rejection diagnosed at the first protocol biopsy. 
Patients were stratified on the basis of histological severity of acute cellular 
rejection.  
 
A. 648 patients, global log-rank p=0.002 
 
 
 
B. 648 patients, global log-rank p=0.008 
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4. ROLE OF BLOOD EOSINOPHIL COUNT IN PREDICTING 
SEVERITY AND CLINICAL COURSE OF ACUTE REJECTION 
AFTER LIVER TRANSPLANTATION 
 
 
4.1 Introduction 
Eosinophils are typically involved in ACR, first reported as an association with 
ACR in kidney transplantation [113], and subsequently in lung and heart 
transplants [114]. In the liver graft, a portal tract eosinophilic infiltrate is a typical 
finding of ACR, which contributes diagnostically, adding to the Banff criteria [102]. 
As graft eosinophils come from blood, a high peripheral eosinophil count might 
predict histological ACR after liver transplantation. Absolute eosinophil count 
(AEC) increases in blood 2–3 days earlier than liver function tests and 3–4 days 
before ACR is proven histologically [115], and there is a positive correlation with 
eosinophilia in the liver graft [116]. 
However the diagnostic utility of blood eosinophilia for ACR has varied. The first 
report [84] found AEC (threshold >0.5 x 109/l) to have a negative predictive value 
(NPV) of 99% and a positive predictive value (PPV) of 44% for ACR. The only 
prospective study included only 20 patients [117]. Other studies [86, 115, 118] 
showed that AEC was a specific predictor of ACR with a high negative predictive 
power, but with inadequate sensitivity and low positive predictive power. In 
addition the predictive ability of a reduction in AEC following treatment of ACR is 
less studied [84, 86, 117, 118]. 
Previous studies have important limitations. Firstly, the major endpoint was 
prediction of any degree of ACR. However mild rejection is usually not treated 
and maintenance immunosuppression is not modified [119]. Secondly the sample 
size was insufficient to perform multivariate analyses, and inadequate to address 
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whether combining liver function tests and eosinophil count could predict ACR 
more accurately. Finally several biopsies were evaluated per patient without 
differentiating the interval from transplantation, thus introducing systematic 
errors, and making results less clinically relevant. 
 
 
4.2 Materials and Methods 
We identified 690 patients in our prospectively collected liver transplant database 
between October 1988 and February 2008 during which interval protocol biopsies 
were obtained 5-7 days after first liver transplantation to establish the presence 
and severity of ACR. There were another 75 patients in whom graft biopsy was 
not available in the first 2 weeks after transplant because of early death (n=20), 
re-transplant (n=13) or other complications and were not analysed. Routine 
laboratory tests including liver function profile were evaluated on the day of the 
biopsy. AEC (normal range 0-0.46 x 109/l) was recorded the day before and on 
the day of the biopsy. Relative eosinophil count (REC) was calculated with the 
following formula: AEC x 100/total white cell count (threshold 3.5%).  
AEC on the day of the second biopsy and ΔAEC between the first and second 
biopsy were evaluated as potential predictors of clinical course of ACR and 
response to treatment. The threshold chosen for ΔAEC was the null value (0 x 
109/l), which meant no change in eosinophil count between the first and second 
biopsy. 
Liver biopsies were examined to assess and grade ACR according to the Royal 
Free system [102], which predates the Banff schema [12]. The Royal Free ACR 
system applies the same histopathological diagnostic criteria (mixed mainly portal 
inflammation, endothelitis and bile duct damage) as the Banff schema, except 
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that the Royal Free system evaluation of eosinophils in the inflammatory infiltrate 
is included as a separate additional axis of assessment. The immunosuppression 
protocol started immediately after transplant with intravenous methylprednisolone 
(1 mg/kg/day until July 1997 or 16 mg daily thereafter, followed in both cases by 
20 mg oral prednisolone daily once gut function was restored) and AZA (1 
mg/kg/day) in addition to either Tac (initially 0.1 mg/kg/day in two divided doses) 
or CsA (initially 10 mg/kg/day in two divided doses). CNI doses were run on the 
lower side of the therapeutic range and adjusted according to serum levels, the 
presence of infection or toxicity. Between October 1996 and January 1997 a 
clinical trial was conducted [99] during which patients were randomized to receive 
monotherapy with Tac versus CsA. From May 1997 to April 1999 patients were 
randomized to triple therapy based on either Tac or CsA [100]. Thereafter a 
cohort of patients received Tac monotherapy [101]. At all times standard 
treatment for ACR consisted of 1 g of intravenous methylprednisolone given on 
three consecutive days. However 28 patients (9.5%) received two boluses and 
20 patients (6.8%) received just one bolus because of individual clinical 
circumstances. 
In 487 patients, a second biopsy was obtained after 6.1±2 days from the first one 
to assess the course and response to treatment. We evaluated the whole group 
for the presence of ACR, and then patients who had or who had not received 
boluses of steroids in relation to the change in eosinophil count. According to the 
grade of ACR in the second biopsy, patients were classified in three groups: (i) 
improvement: when ACR grade improved from moderate or severe to mild or no 
ACR; (ii) deterioration: opposite of the previous; (iii) no change: when no 
significant histological change was found. 
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Statistical analysis 
Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, USA). 
Variables are displayed in frequency tables or expressed as means and standard 
deviations, except those with an asymmetric distribution, which are described 
with medians and interquartile ranges (IQR). Testing for differences between 
groups were performed using Chi square test for frequencies, student’s t test or 
anova tests for quantitative variables and Mann–Whitney’s U test or Kruskal-
Wallis for variables with an asymmetric distribution. The optimal threshold value 
for peripheral eosinophil count with respect to moderate/severe ACR was 
established by receiver operating characteristic (ROC) curves. We used multiple 
logistic regression to control for possible confounding factors and to evaluate the 
combination of eosinophil count and other routine laboratory tests, which have 
also been used in previous papers, (AST, ALT, AST/ALT ratio, ALP, GGT, 
bilirubin, albumin, urea and creatinine) in predicting moderate/severe ACR. The 
same method was used to identify those variables independently related with 
histological improvement of ACR. Every hypothesis tested was two tailed and 
considered statistically significant if p<0.05. 
 
 
4.3 Results 
 
4.3.1 Descriptive evaluation 
There were 690 patients of whom 425 (61.6%) were men. Major aetiologies were 
alcoholic liver disease (17.1%), HCV (13.3%), or their combination (5.1%), HCC 
(11.4%), PBC (13%), ALF (8%), PSC (7%), HBV (5.8%) and cryptogenetic 
cirrhosis (5.1%). A protocol liver biopsy was obtained 6±2.5 days after liver 
transplantation. ACR was found in 532 patients (77.1%) which was mild in 294 
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(42.6%), moderate in 211 (30.6%) and severe in 27 (3.9%) biopsies respectively 
and 158 patients (22.9%) had no histological ACR. In 294 cases (42.6%) boluses 
of corticosteroids were given after the first biopsy, with 90 (30.6% treated) 
patients having mild ACR, 178 (84.4% treated) moderate ACR and 26 (96.3% 
treated) severe ACR. 
A second biopsy was taken 6.5±2 days after the first one in 487 patients (70.6%). 
The group who had a second biopsy had more severe ACR on the first biopsy 
(moderate-severe rate 42.3% vs. 15.8%; p<0.001) and subsequently received 
more corticosteroid boluses and AZA (Table 4.1).  
In the group that had received bolus steroids, an improvement was seen in 102 
(40.6%) patients, 23 (9.2%) showed deterioration and 126 (50.2%) remained 
unchanged. With regard to the patients who did not receive bolus of steroids 
initially, only 17 (7.2%) improved while 56 (23.7%) showed deterioration and 163 
(69.1%) remained unchanged. Considering subgroups according to the grade of 
ACR on the first biopsy, of 99 patients initially classified as ‘no ACR’ 37 (37.4%) 
remained unchanged while 62 patients worsened (45.5% to mild ACR and 13.1% 
to moderate-severe ACR). From 182 patients with mild ACR on the first biopsy, 
improvement to no ACR was seen in 30 patients (16.5%) and deterioration to 
moderate-severe ACR occurred in 66 patients (34%). Finally from 206 patients 
with moderate-severe ACR at baseline, improvement was detected in 119 cases 
(97 (47.1%) passed to mild ACR, and 22 (10.7%) to no ACR). 
 
4.3.2 Laboratory variables as predictors of moderate or severe ACR 
The univariate analysis showed that both AEC and REC were higher in ACR 
patients especially when moderate-severe ACR occurred (Figure 4.1).  
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In the ROC analysis, the area under curve was 0.58, 0.59 and 0.57 for AEC, AEC 
(day-1) and REC respectively. Values of sensitivity, specificity, PPV and NPV 
tested for several cut-off points related to moderate or severe ACR are shown in 
Table 4.2.  
It is noteworthy that, although sensitivity and specificity vary (occasionally 
exceeding 90%) depending on the cut-off point chosen, predictive values for 
moderate/severe ACR are relatively constant and lower than 70% for most 
scenarios. 
The initial immunosuppression regimen used immediately after transplantation, 
and the indication for liver transplant did not influence either AEC or grade of 
ACR. Nevertheless those patients with PSC showed higher levels of AEC (0.6 x 
109/l; IQR 0.14-1.3) at first biopsy than other indications (0.3 x 109/l; IQR 0.16-
0.52) (p=0.01). 
Patients with moderate to severe ACR were also characterized by higher bilirubin 
and cholestasis parameters with lower AST, AST/ALT ratio, albumin, urea and 
creatinine (Table 4.3) than those with mild or no ACR. Serum bilirubin, GGT, 
albumin, urea and AEC on the day of biopsy were independently related with the 
degree of ACR in the multivariate analysis (Table 4.3).  
The combination of these serum parameters in the logistic regression analysis 
had 73% sensitivity and 52.9% specificity which was only a marginal 
improvement compared with AEC alone (global precision improved from 0.62 to 
0.65). ALP and creatinine were tested within the model instead of GGT and urea 
respectively, but they did not reach statistical significance. It is noteworthy that 
the ALT value, which is widely used as a marker of ACR in clinical practice, was 
not related to the presence or grading of ACR (Figure 4.2). The ALP was related 
to ACR but because of the wide overlap it cannot be used as a marker of ACR 
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nor its severity (Figure 4.2). The immunosuppression regimen and the indication 
for liver transplant (primary sclerosing cholangitis) were both included and then 
excluded as possible confounding factors for the association between AEC and 
grade of ACR (Table 4.3).  
 
4.3.3 Peripheral eosinophil count as biological marker for ACR 
In the second biopsy, 89 cases (18.3%) showed no ACR, 232 (47.6%) had mild 
ACR, 135 (27.7%) moderate ACR and 31 (6.4%) severe ACR. Compared with 
the first biopsy, there was an improvement for 119 patients (24.4%) and 
deterioration for 79 (16.2%) while 289 (59.3%) remained unchanged. The AEC 
on the day of the second biopsy and the change in AEC between the first and the 
second biopsy were closely related with the histological course of ACR (Figure 
4.3).  
A decrease in AEC was associated with an improvement of the histological grade 
of ACR. In the ROC curve the AUC for ΔAEC was 0.72 (95% CI 0.66-0.78) while 
for AEC on the day of the second biopsy it was 0.34 (95% CI 0.27-0.40). The 
best threshold for ΔAEC was no increase i.e. 0 x 109/ l (Sensitivity = 75%; 
Specificity = 64%). In the subgroup of patients with moderate-severe ACR on the 
first biopsy, AEC decreased in those patients who achieved histological 
improvement (ΔAEC = 0.19x109/l; IQR 0.007-0.46) while a trend to rise in AEC 
was seen in patients who remained unchanged (ΔAEC = -0.06x109/l; IQR -0.23 – 
0.27), with statistically significant differences between them (p<0.001). With 
regard to liver function tests, there was a trend to a rise in parameters of 
cholestasis (GGT and ALP) between the first and the second biopsy, which was 
significantly greater for ALP in those cases without improvement in the second 
biopsy (Table 4.4). Nevertheless in the multiple logistic regression, the only 
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independent predictors of good histological course were ΔAEC and treatment 
with boluses of steroids (Table 4.4). 
In the present cohort, 108 patients at the first biopsy had ALT levels lower than 
100 IU, and among these 39 patients (36.1%) showed moderate or severe ACR. 
In this subgroup of patients, the ΔAEC was more accurate in predicting clinical 
course of ACR. In the ROC curve, the area under the curve was 0.81 and, with a 
threshold of no increase i.e. 0 x 109/l, the sensitivity was 82% and specificity was 
69%. 
 
4.3.4 Blood eosinophils and histological improvement of ACR 
AEC on the day of the first biopsy was comparable between patients who had a 
second biopsy and patients without a second biopsy (0.33 x 109 IQR 0.17–0.58 
vs. 0.30 x 109 IQR 0.14–0.5; p=0.44). Among the patients with a second biopsy, 
the subgroup, who received boluses with steroids achieved improvement in the 
biopsy grade of ACR (102/251; 40.6%), more frequently than the subgroup who 
did not receive bolus steroids (17/236; 7.2%) (p<0.001). This may be explained in 
part because of differences in the grade of ACR in the first biopsy (Figure 4.4). 
In the subgroup of 251 patients who were given corticosteroids boluses, AEC on 
the day of the second biopsy and ΔAEC between the first and the second biopsy 
were related to the likelihood of treatment response (p=0.001 and p<0.001 
respectively) (Figure 4.5). In the ROC curve, the area under curve for ΔAEC was 
higher (0.66) than for AEC on the day of the second biopsy (0.35). An AEC rising 
higher than 0.3 x 109/l between the first and second biopsy was associated with a 
high likelihood of no response to bolus steroids (78.3%), with a sensitivity for this 
threshold of 94.8%. Among patients with moderate-severe ACR on the first 
biopsy who received bolus steroids, the AEC decrease was greater in those 
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cases with improvement (ΔAEC = 0.19 x 109/l; IQR 0–0.48) compared with those 
who did not (ΔAEC = -0.04 x 109/l; IQR -0.23–0.38; p=0.001). Improvement in 
grade of ACR was also more frequent in patients who received 3 boluses of 
steroids (97/212; 45.8%) than in those who received a lower dose (5/39; 12.8%) 
(p<0.001); nevertheless the number of boluses did not influence AEC on he day 
of the second biopsy (p=0.63) and neither ΔAEC between the first and second 
biopsies (p=0.21). The delta value of liver function tests (bilirubin, AST, ALT, 
AST/ALT ratio, ALP and GGT) did not correlate with the likelihood of treatment 
response (p=0.22, p=0.89, p=0.31, p=0.34 and p=0.11 respectively). The 
multivariate analysis (which included ΔAEC, steroid dose, immunosuppression 
protocol and delta of liver function tests) identified ΔAEC as the only independent 
variable able to predict the histological response of ACR after treatment with 
boluses of steroids (OR=2.77; 95%CI 1.4-5.5; p=0.004) although the association 
was marginally less than in the group overall (OR decreased from 3.12 to 2.77). 
With regard to the subgroup of 236 patients who had not received steroids, the 
ΔAEC, but not the AEC, on the day of the second biopsy was related to the 
likelihood of ACR improvement (p=0.009 and p=0.11 respectively) (Figure 4.5). 
Delta values of bilirubin, AST, ALT, and GGT between the first and the second 
biopsies were not related to the likelihood of ACR improvement in the second 
biopsy (p=0.19, p=0.91, p=0.23 and p=0.08 respectively). As described 
previously in the whole cohort, a larger difference in ΔALP was seen in the group 
who did not improve (106 vs. 23 IU/l; p=0.015). Among patients in this group with 
moderate-severe ACR on the first biopsy, the AEC decreased in those patients 
who improved (ΔAEC = 0.21 x 109/l; IQR 0.02–0.24) while it increased in those 
who did not (ΔAEC = -0.11 x 109/l; IQR -0.37–0; p=0.008). Multivariate analysis 
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could not be performed in this subgroup because of the small number of patients 
that improved the grade of ACR in the second biopsy (n=17). 
 
 
4.4 Discussion and conclusions 
This study evaluated the clinical usefulness and accuracy of peripheral blood 
eosinophil count for predicting moderate and severe ACR, as well as its clinical 
course and response to treatment with steroids in a large cohort of liver 
transplant patients. Since there is no consensus on the definition of ACR based 
on liver function tests, which are also poorly correlated with its grade, histological 
ACR was used as the gold standard to evaluate the accuracy of eosinophils. 
Absolute eosinophil count measured on the day before or on the day of the 
biopsy was higher in patients with ACR, which is in agreement with previous 
reports [84, 86, 116-118], and was related to the histological grade of rejection 
confirming our previous observations in 275 liver biopsies from 101 patients [86]; 
this correlation is more likely as eosinophils in the histological infiltrate are an 
independent marker of ACR [102]. However using the upper limit of normal range 
(0.46 x 109/l) the PPV and NPV were only 66.5% and 51.9% respectively. Even 
when thresholds with a higher sensitivity and specificity were tested, the 
predictive values did not exceed 70% in any situation, so this parameter is not 
itself sufficiently predictive to guide therapeutic decisions. Our results do not 
confirm the high NPV in 51 patients [115], and in 60 patients [84], nor high 
specificity in 167 patients [118] of a raised AEC, found in previous studies. 
Other studies have shown that several routine biochemical laboratory tests are 
related to the presence of ACR [87, 90, 120]. When we assessed these 
parameters in association with the AEC in predicting moderate-severe ACR, the 
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AEC was the strongest related parameter (OR = 2.15) and a higher bilirubin and 
GGT with a lower albumin and urea, independently predicted moderate-severe 
ACR. However, the combination of these tests only marginally improved the 
global precision of AEC (0.62 to 0.65). Thus the benefit of combining AEC with 
routine biochemical laboratory tests was limited. 
Previous studies [84, 86] did not evaluate relationships between peripheral 
eosinophil counts and histological changes. A higher AEC or REC before 
treatment predicted biochemical response to bolus corticosteroids with a 
sensitivity and specificity ranging from 45% to 50% in one study of 140 paired 
biopsies [118]. In our study, only the ΔAEC between the first and second biopsy 
and treatment with bolus steroids were independent predictive factors for 
histological improvement in the multivariate analysis. In the group overall the 
sensitivity and specificity of ΔAEC for predicting improvement was 75% and 64% 
respectively (threshold 0 x 109 which meant no difference in ΔAEC between the 
first and second biopsies). These results were consistent among the group of 
patients with moderate-severe rejection on the first biopsy. Importantly when 
transaminases were low (ALT <100 IU/l), the accuracy of DAEC was improved 
(sensitivity 82% and specificity 69%). Thus ΔAEC is a simple non-invasive 
parameter that helps to assess the course of ACR, whereas differences in 
standard liver function tests were not helpful. 
In patients treated with boluses of corticosteroids, it is reasonable to expect a 
lower predictive power for ΔAEC because steroids lower blood eosinophil counts. 
However this was not a major issue: OR for ΔAEC in the multivariate analysis 
decreased from 3.12 in the group overall to 2.77 in the bolus corticosteroid group. 
The ΔAEC was not affected by type of maintenance immunosuppression 
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including steroids, which were used at much lower doses compared with bolus 
doses. 
In conclusion, we found that, although the AEC is independently related to 
moderate and severe ACR, its predictive power is not accurate enough to make 
therapeutic decisions using this parameter alone. The combination of AEC with 
other ACR independently associated variables (i.e. bilirubin, GGT, albumin and 
urea) only had a marginal benefit in terms of diagnostic precision. However, the 
changes in AEC used as a monitoring test can provide valuable information 
about the histological course and the likelihood of response to boluses of steroids 
for treatment of moderate-severe rejection. This finding is particularly useful if 
biopsies are not routinely performed to diagnose acute cellular rejection and 
assess response to therapy. Nevertheless it would be useful to have a 
consensus definition for clinical rejection, which might include peripheral 
eosinophil count and would need a correlation with protocol biopsies. 
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4.5 Tables and figures 
 
 
Table 4.1. Baseline characteristics in patients who had a protocol first liver 
biopsy after transplantation (days 6±2.5) who then had or did not have a second 
biopsy. 
 
 Group with 2nd 
biopsy (n=487) 
Group without 2nd 
biopsy (n=203) p 
Moderate/severe ACR at first 
biopsy 
206 (42.3%) 32 (15.8%) <0.001 
Tacrolimus 343 (70.4%) 155 (76.4%) 0.11 
Ciclosporine 113 (23.2%) 38 (18.7%) 0.19 
Azathioprine 214 (43.9%) 69 (34%) 0.015 
Mycophenolate 50 (10.3%) 19 (9.4%) 0.71 
Prednisone 226 (46.4%) 93 (45.8%) 0.88 
Steroid boluses 251 (51.5%) 43 (21.2%) <0.001 
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Table 4.2. Accuracy of AEC and REC to predict histological moderate or severe 
rejection in the first (protocol) biopsy after liver transplantation (days 6±2.5). 
Normal range of AEC: 0-0.46 x109/L where 0.46x109/L is the upper limit of the 
normal range. 
 
 
Cut-off 
point Sensitivity Specificity PPV NPV 
AEC (x109) 
1 8.2% 93.6% 44.4% 62.7% 
0.46 43.8% 73% 49.7% 68.1% 
0.2 70.6% 39.5% 41.5% 68.9% 
0.1 86.6% 21% 40% 72% 
AEC (day-1) 
(x109) 
1 2.7% 96.7% 33.3% 61.9% 
0.46 27.3% 79.4% 44.7% 64.1% 
0.2 62.6% 52.6% 44.7% 69.7% 
0.1 78.1% 37.9% 43.5% 70.9% 
REC (%) 
6 25.7% 76.2% 40% 62.4% 
3.5 57.2% 55.4% 44.2% 66.7% 
2.5 70.1% 45.5% 44.3% 71.1% 
1.2 81.8% 29.4% 41.7% 72.4% 
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Table 4.3. Relationship between laboratory variables and histological grade of 
rejection in the first protocol liver biopsy after liver transplantation (days 6±2.5). 
Univariate analysis and multiple logistic regression (n=690 patients).  
 
 Unadjusted Analysis 
Histological ACR 
Adjusted Analysis 
Moderate-severe ACR 
None-mild Moderate-severe  p OR (95%CI) p 
AEC (x109/L) 0.28 (IQR 0.13, 0.5) 0.40 (IQR 0.18-0.64) <0.001 2.15 (1.2-3.8) 0.007 
Bilirubin 
(µmol/L) 
92±82 97.5±76.2 0.39 1.0 (1.0-1.01) 0.04 
AST (IU/L) 88 (IQR 50, 206) 74 (IQR 48, 129) 0.01   
ALT (IU/L) 279 (IQR 136, 565) 250 (IQR 132, 531) 0.65   
AST/ALT 0.53 (IQR 0.32, 0.8) 0.43 (IQR 0.3, 0.7) <0.001   
ALP (IU/L) 106 (IQR 70, 161) 133 (IQR 87, 213) <0.001   
GGT(IU/L) 189 (IQR 105, 328) 284 (IQR 167, 412) <0.001 1.0 (1.01-1.03) 0.003 
Albumin (g/L) 30±8.2 27.4±7.7 <0.001 0.96 (0.93-0.99) 0.02 
Urea (mg/dL) 13.5±8.8 10.6±7.4 <0.001 0.96 (0.93-0.99) 0.04 
Creatinine 
(µmol/L) 
133±73 120.3±72.2 0.034   
 
Confounding factors controlled for: aetiology (primary sclerosing cholangitis, immunosuppression 
(cyclosporine vs. tacrolimus; maintenance prednisone; maintenance azathioprine) 
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Table 4.4. Variables related to histological improvement of acute cellular 
rejection in the second biopsy performed to assess course of rejection (6.1±2 
days after first biopsy). Univariate analysis and multiple logistic regression 
(n=487 patients). 
 
 Univariate analysis Multivariate analysis 
(improvement) 
Improvement No change/ 
deterioration 
p OR CI95% p 
Bolus 
steroids (%) 
102/119 (85.7%) 149/368 (40.5%) <0.001 10.09 4.7-21.4 <0.001 
ΔAEC 
(x109/L) 
0.25 (IQR 0.05-0.5) -0.04 (IQR -0.3, -0.2) <0.001 3.12 1.5-6.2 0.001 
ΔBilirubin 
(µmol/L) 
10.5 (IQR (-25, -38) 5 (IQR -40, -28) 0.16    
ΔAST (IU/L) 15.5 (IQR (-26, -54) 18 (IQR -28, -73) 0.41    
ΔALT (IU/L) 98.5 (IQR 11, 382) 143 (IQR 18, 362) 0.97    
ΔALP (IU/L) -80 (IQR (-241, -7.5) -130 (IQR -269, -17) 0.036    
ΔGGT (IU/L) -38 (IQR (-318, -74)  -138 (IQR -342, 0) 0.095    
 
Confounding factors controlled for: aetiology (primary sclerosing cholangitis, immunosuppression 
(cyclosporine vs. tacrolimus; maintenance prednisone; maintenance azathioprine) 
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Figure 4.1. Absolute eosinophil counts on the day of the biopsy (AEC) and on 
the day before (AEC day-1) and relative eosinophil count (REC) according to 
histological grade of rejection in the first protocol biopsy performed 6±2.5 days 
after liver transplantation. Medians and IQR are shown. 
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Figure 4.2. ALT and ALP concentration and histological level of rejection in the 
first protocol liver biopsy performed 6±2.5 days after liver transplantation. 
 
A. 
 
 
B. 
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Figure 4.3. Delta of absolute eosinophil count (ΔAEC) between the first protocol 
biopsy and the second biopsy and absolute eosinophil count on the day of the 
second biopsy (AEC 2ndbx) after liver transplantation and their relationship with 
histological change of rejection in the whole cohort (n = 690). Medians and IQR 
are shown. 
 
A. 
 
 
 
B. 
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Figure 4.4 Grade of ACR in the first protocol biopsy after liver transplantation 
depending on whether boluses of steroids were subsequently given. The 
proportion of moderate/severe rejection was higher at baseline in the steroid 
group (p<0.001). 
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Figure 4.5. Delta of absolute eosinophil count (ΔAEC) between the first protocol 
biopsy and second biopsy after liver transplantation and absolute eosinophil 
count on the day of the second biopsy (AEC 2ndbx) related to histological course 
of rejection whether boluses of steroids were used (n=251) or not (n=236). 
Medians and IQR are shown. 
 
A. 
 
 
 
B. 
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5. IMMUNE MONITORING BEFORE AND AFTER LIVER 
TRANSPLANTATION 
 
 
5.1 Introduction 
Measuring the concentration of immunosuppressive drugs in the serum of 
patients is generally used as a surrogate for the level of immunosuppression, but 
it does not provide information about the magnitude of suppression of the 
immune system. In addition, there is generally a poor correlation between ACR 
and immunosuppression levels or the degree of liver test abnormalities. 
Therefore a marker for the appearance of ACR, or able to predict patients who 
could tolerate reduced immunosuppression, would be important for improving 
post-transplant management of liver transplanted patients. 
In the cascade of events inducing ACR, the second signal is represented by the 
interaction between the CD28 molecule and the B7 ligand [121]. On the other 
hand the expression of CD38, a marker of activation of T-lymphocytes [122], has 
been shown to be a marker of cytomegalovirus infection in transplant recipients 
[123]. Therefore the expression of these two proteins should be evaluated as 
potential marker of immunological status. 
Recent studies have shown that a distinct Treg subset expressing CD4, CD25, 
the α-chain of the IL-2 receptor, and the transcription factor Foxp3, was able to 
suppress activation of effector T cells [124, 125]. Tregs can also play a central 
role in modulating allograft rejection in animal models of transplantation [126-
128]. These data have suggested that the presence of Tregs in the periphery 
may be crucial to allow graft acceptance and possibly to develop tolerance. 
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However, there is little information about the clinical significance of circulating 
Tregs in liver transplanted patients. 
Lastly, Th17 cells have been cast as major players in autoimmunity, but their 
specific role in allograft rejection is under investigation. In the peri-transplant 
period, the production of pro-inflammatory cytokines such as IL-6, TNF-α, TGF-β, 
IL-12, and IFN-γ promote the acquisition of cytodestructive Th1 and Th17, 
characterized by the production of IL-17. This induces the generation of graft-
destructive lymphocyte populations and simultaneously blocks the development 
and suppressive function of Tregs [129, 130]. It has been shown that the 
presence of Th17 cells in the allograft might be a biomarker of detrimental tissue 
inflammation rather than part of a mechanism that mediates graft destruction 
[129-134]. Despite in renal transplanted patients a link has been found between 
IL-17 and ACR [135, 136], data in liver transplant setting are still controverse.  
 
 
5.2 Materials and Methods 
 
5.2.1 Patient cohort 
Patients listed for liver transplantation and transplanted at the Royal Free 
Hospital (London, UK) were included in this prospective study. 
Inclusion criteria were: age ≥17 years, written informed consent, and follow-up 
after liver transplantation performed at Royal Free Hospital.  
Patients transplanted for acute liver failure were excluded from the study. 
Patients considered vulnerable, such as patients with learning difficulties or with 
English as a second language, were included in this study, only if it was felt that 
the research might have benefit them. Vulnerable patients were enrolled into the 
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study providing that they had a good general understanding of what is being 
investigated. Translators were available to explain the study if required. 
Peripheral blood samples were obtained from all patients before (at the time of 
listing and/or at the day/night of transplantation) and after liver transplantation at 
specific time points (day 3, day 5, day 15, day 30, day 60), as well as at time of 
protocol liver biopsy or if patients were readmitted after discharge. 
The first protocol liver biopsy was planned between 7 and 13 days after liver 
transplantation. All biopsy samples were fixed in formalin and embedded in 
paraffin. Histological sections (4 µ thick; 3 levels through the tissue block) were 
stained with hematoxylin and eosin, and other histochemical stains were 
prepared as required.  
The diagnosis of ACR was based on pathologic findings, using the Banff 
classification [12]. Patients who developed ACR were treated with 1g of 
intravenous methylprednisolone given on three consecutive days. 
 
5.2.2 CD25, CD28 and CD38 assessment  
Heparinized blood was diluted 1/1 with RPMI 1640, then incubated for 30 min at 
room temperature in the dark with monoclonal antibodies anti cell surface 
antigens CD25, CD28 and CD38. Erythrocytes and were lysed by incubation with 
FACS lysing solution (Becton Dickinson, USA) for 10 min at room temperature in 
the dark, and then washed in a buffer consisting of phosphate buffered saline 
containing 2% bovine serum albumin. Mononuclear cells were obtained from 
heparinized blood by density gradient centrifugation over Ficoll-Paque plus 
(Amersham Biosciences, United Kingdom). Cells were then fixed by incubation 
with 0.3% paraformaldehyde-phosphate-buffered saline and stored at 4°C until 
analysis. 
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Flow cytometric analysis was performed on a FACScan flow cytometer (Becton 
Dickinson, USA). Expression levels of molecules on lymphocytes were measured 
using 4-color surface staining using Phycoerythrin (PE), fluorescein 
isothiocyanate (FITC), peridin chlorophyll protein (PerCP), and allophycocyanin 
(APC)-labelled antibodies: anti-CD4 (mouse IgG1, PerCP), anti-CD8 (mouse 
IgG1, FITC), anti-CD28 (mouse IgG1, PE) anti CD38 (mouse IgG1, PE), anti-
CD25 (mouse IgG1, FITC). All monoclonal antibodies, were obtained from 
Becton Dickinson. We used the Flow Jo 7.3.5 (Treestar Software, Inc., Ashland, 
Ore) for Windows system for all data analysis. 
 
5.2.3 Assays of IL-17 
Serum samples were obtained from clotted blood after centrifugation at 2000g for 
15 minutes within 20 minutes of collection, and the serum was stored at -20°C 
until analysis was performed. IL-17 circulating levels were determined by 
quantitative enzyme linked immunosorbent assay (ELISA) with the commercial 
human IL-17A ELISA Ready-SET-Go kit (eBioscience, San Diego, CA).  
 
5.2.4 Statistical analysis 
Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, USA). 
Variables are displayed in frequency tables or expressed as means and standard 
deviations, except those with an asymmetric distribution, which are described 
with medians. Testing for differences between groups were performed using Chi 
square test for frequencies, student’s t test or anova tests for quantitative 
variables and Mann–Whitney’s U test or Kruskal-Wallis for variables with an 
asymmetric distribution. 
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5.3 Results 
Between June 2011 and October 2012, 79 patients were transplanted at the 
Sheila Sherlock Liver Centre, Royal Free Hospital (London, UK). Amongst these 
8 patients were excluded because transplanted for ALF. Amongst the remaining 
71 patients, 66 agreed to participate in the study. 5 patients drop out because of 
non-adherence to indications (n=4) and because of personal reasons (n=1), 
leaving 56 patients for the analysis.  
Nearly half of the patients were male (55.5%), with a mean age±SD of 49.7±10.5. 
The most frequent indication to liver transplantation was alcohol related liver 
cirrhosis (28.5%), followed by cholestatic liver disease (21.5%). Mean MELD 
score at the time of liver transplantation was 15.5±30.5, and the mean time on 
the waiting list was 188.6±30.5 days (Table 5.1). 
Mean donor age was 44.8±15.3, all the transplants were performed with an 
identical ABO group matching and the mean cold ischemia time was 6.58±2.32 
hours (Table 5.1)  
ACR was diagnosed in 9 patients: 6 (66.7%) mild, 2 (22.2%) moderate and 1 
(11.1%) severe. Demographic and clinical characteristics of patients with ACR 
are reported in Table 5.1. 
 
5.3.1 Levels of Tregs before and after liver transplantation 
Patients with cholestatic liver disease presented the lowest expression of 
CD4+CD25+ (2.9±1.8%) when compared to patients with alcoholic liver disease 
(4.5±1.5%; p=0.02), virus-related liver disease (6.9±2.4%; p<0.001) and other 
aetiologies (4.8±1.7%; p=0.02) (Figure 5.1). When levels of Tregs were evaluated 
according to the interval time from liver transplantation, we found that the lowest 
levels were within the first week after liver transplantation (1.2±0.4%) followed by 
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a progressive increase at day 15 (2.6±0.3%; p=0.01), day 30 (3.0±0.2%; 
p=0.001) and day 60 (3.2±0.2%; p=0.001). No statistical difference was seen in 
terms of Tregs levels between day 30 and day 60 (Figure 5.2). 
Levels of Tregs were then assessed after stratification patients according to the 
presence/absence of ACR. Patients with ACR showed a similar expression of 
CD25+CD4+ T cells compared with patients without ACR when the assessment 
was performed before liver transplantation (3.2±0.5% vs. 3.4±0.8%; p=0.57) 
(Figure 5.3A), whereas after liver transplantation patients who experienced ACR 
presented a significantly lower percentage of CD25+CD4+ T cells compared to 
patients without ACR (1.99±0.6% vs. 4.0±0.8%; p=0.001; Figure 5.3B). 
 
5.3.2 CD28 and CD38 as potential markers of ACR 
The mean frequencies of CD28+CD4+ T cells and of CD38+CD4+ T cells were 
significantly higher in patients with ACR compared with patients without ACR at 
day 5 (52.1±3.2% vs. 45.7±8.4%; p=0.01 and 45.6±9.3% vs. 32.3±8.1%; p=0.002 
respectively) and at the day of ACR diagnosis (54.6±4.6% vs. 43.3±5.2%; 
p=0.001 and 39.4±12.1% vs. 27.5±7%; p=0.001 respectively). No difference 
between the two groups was found on samples taken on day 3 (Figure 5.4A and 
5.4B). 
When the expression of CD28 and CD38 was evaluated on CD8+T cells similar 
results were found. Patients with ACR presented a significantly higher expression 
of both CD28 and CD38 compared with patients without ACR at day 5 
(57.4±9.6% vs. 43.3±8.1%; p=0.03 and 54±8.4% vs. 39.2±7.6%; p=0.001, 
respectively), and at day of liver biopsy (59.5±8.1 vs. 44.2±6.3%; p=0.02 and 
49.1±11.3% vs. 30.4±8.7%; p=0.001 respectively) (Figure 5.5A and 5.5B). 
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In order to evaluate the potential influence of infections on the expression of 
CD28 and CD38, the same analysis was repeated after dividing patients into 
three subgroups: a) patients with ACR; b) patients who experienced an infective 
complications; c) patients without ACR nor infection. Again patients with ACR 
presented a significantly higher expression of CD28 and CD38 compared to 
patients without ACR and without infection. Conversely no difference was found 
in terms of CD28 and CD38 expression between patients with infection and those 
without events (data not shown). 
 
5.3.3 Levels of IL-17 after liver transplantation 
The concentration of IL-17 at day 3, and day 5 after liver transplantation did not 
differ between patients who experienced ARE and patients without ACR. 
Conversely, when the concentration of IL-17 was measured the day of ACR 
diagnosis, we found that the patients with ACR presented a significantly higher 
levels of IL-17 compared with patients without ACR (14.2±3.5 pg/mL vs. 7.9±2.4 
pg/mL; p<0.001) (Figure 5.6). We also observed that, in patients experiencing 
ACR, the levels of IL-17 tended to increase from day 3 until the day of ACR 
diagnosis, slightly decreasing afterward (Figure 5.6). In patients without ACR 
these changes in IL-17 were not seen with IL-17 remaining substantially stable 
overtime.  
 
 
5.4 Discussion and conclusions 
Today, the administration of immunosuppression is considered more of an art 
than a science. Indeed, there are not reliable markers of the immunological 
status of organ transplanted patients. Moreover, there is generally a poor 
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correlation between ACR and immunosuppression levels, with liver biopsy still 
remaining the gold standard for the diagnosis of ACR. In this contest it is 
becoming crucial to identify potential markers of immune activity to adjust 
immunosuppressive therapy according to the real suppression of the immune 
system. 
In this study, we prospectively assessed patients before and after liver 
transplantation and we evaluated the potential role of expression of different 
proteins and interleukin as potential markers of immune status. 
Considering Tregs, their role in transplantation has been evaluated mainly in 
animal studies, which showed that the transfer of Tregs from long-term tolerant 
mice to allografted posts prevents rejection of transplanted allogeneic pancreatic 
islets or skin (8,17). These studied concluded that an increased number of 
circulating Tregs may be beneficial for allograft survival. However their role in 
mediating ACR in human liver transplant recipients is still controversial. 
In our study pre-transplant frequencies of circulating Tregs were not different 
between patients with and without ACR, therefore their evaluation in the pre-
transplant phase might not be useful in order to discriminate between patients 
who will develop ACR after liver transplantation and those who will not develop it. 
Conversely, in the post-transplant period we found that patients with ACR 
presented significantly levels of Tregs compared with patients without ACR. The 
cause of this low expression in patients with ACR is still under debate, but we 
could speculate that circulating Tregs cells may be recruited in other 
compartments, such as the graft or secondary lymphoid organs. Further 
prospective studies, possibly including analysis of the expression of Tregs in the 
graft, are needed to properly understand the role of this subset of T cells in 
modulating ACR and graft acceptance. 
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With regards to other proteins expressed on activated T cells, CD28 and C38 
represents two of the most interesting ones. The interaction between CD28 is the 
B7 ligand is necessary as a second signal in the ACR pathway [121], and CD38 
has been shown to be an early marker of cytomegalovirus infection in transplant 
recipients [123], but its role on T cell activation is still unclear. In our study 
patients experiencing ACR showed increased expression of CD28 and CD38 on 
both CD4+ and CD8+ T cells compared with patients without ACR. Interestingly 
this difference was evident on day 5 post-transplant and on the day of liver 
biopsy, whereas no difference was found at baseline between the two groups. 
In line with our results, a French group showed that patients with ACR presented 
a significantly higher expression of CD28 and CD38 on CD3, CD4 and CD8 T 
cells populations compared to patients without ACR [137]. This expression 
decreased after anti-rejection therapy. Although in this study the CD28 and CD38 
expression levels did not change in patients suffering from an acute CMV 
infection, previous papers have shown alterations in the CD28 and CD38 pools 
during CMV infection [138, 139], limiting its clinical use. 
Lastly, we observed that IL-17 levels were higher in patients with ACR compared 
with patients with no ACR, but this difference was evident only the day of liver 
biopsy. These results are in line with the study Caldwell et al. [140], who found 
that hepatic ischemia reperfusion injury led to the induction of Th17 cells. In a 
experimental model of lung ischemia reperfusion injury an early activation of 
Th17 cells was observed [141]. A potential role of IL-17 in mediating ACR has 
been also demonstrated in renal [135, 142] and heart [143, 144] transplant 
recipients.  
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In conclusion, our study demonstrated that there are specific alterations of 
immune system, which could be used routinely in clinical practice to assess the 
immune status of liver transplanted patients and to monitor those ones who are 
at risk of ACR. Due to the small number of patients included in the present study, 
it’s difficult to estimate the reliability of these markers, however we believe that 
future studies should address the question by a simultaneous evaluation of 
different parameters and biomarkers. This approach could lead to a more 
appropriate use of immunosuppression and to a reduced incidence of 
immunosuppression-related side effects. 
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5.5 Tables and figures 
 
Table 5.1. Demographic and clinical characteristics of all 56 transplanted 
patients, and of patients experiencing acute cellular rejection (n=9). 
 
 Study cohort 
n=56 (%) 
Patients with ACR 
n=9 (%) 
Recipient gender 
  Male 
  Female   
 
31 (55.3) 
25 (44.7) 
 
3 (33.3) 
 6 (66.7) 
Recipient age, years (mean±SD) 49.7±10.5 50.4±11.2 
Liver disease 
  ALD 
  HBV 
  HCV 
  Cholestatic 
  Other 
 
16 (28.5) 
8 (14.3) 
9 (16) 
12 (21.5) 
11 (19.7) 
 
1 (11.1) 
1 (11.1) 
2 (11.1) 
3 (33.4) 
2 (22.3) 
MELD (mean±SD) 15.5±30.5 12.5±3.35 
UKELD (mean±SD) 52.1±8.3 49.6±12.1 
Donor gender 
  Male  
  Female 
 
 18 (32.1) 
38 (67.9) 
 
 5 (55.6) 
4 (44.4) 
Donor age, years (mean±SD) 44.8±15.3 45.8±16.2 
ABO-group matching 
  Identical 
  Compatible 
  Incompatible 
 
 56 (100) 
(0) 
(0) 
 
9 (100) 
(0) 
(0) 
IS regimen at day 1 
  Mono 
  Double 
  Triple 
 
25 (44.6) 
13 (23.2) 
18 (32.2) 
 
3 (33.3) 
1 (11.1) 
5 (55.6) 
Cold ischemia time, min (mean±SD) 6.58±2.32 7.64±1.95 
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Figure 5.1 Levels of Tregs in patients patients before liver transplantation 
according to the aetiology of liver disease. Patients with cholestatic liver disease 
presented significantly lower levels of Tregs compared to other groups (p<0.001 
vs. viral; p=0.02 vs. alcohol and other). 
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Figure 5.2. Change over time of Tregs levels in patients before and after liver 
transplantation, evaluated at fixed intervals. Levels at day 5 were significantly 
lower compared to levels at day 15 (p=0.01), day 30 (p=0.001) and day 60 
(p=0.001). No statistical difference was seen in terms of Tregs levels between 
day 15, day 30 and day 60. 
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Figure 5.3. Levels of Tregs in patients before (A) and after liver transplantation 
(B) according to the presence or absence of ACR.  
 
 
A. Before liver transplantation (p=0.57) 
 
 
 
B. After liver transplantation (p=0.001) 
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Figure 5.4 Expression of CD28 (A) and CD38 (B) on CD4+ T cells (B) from day 3 
until the day of ACR diagnosis. Patients were stratified according to the 
presence/absence of ACR. Expression of CD28 and CD38 were significantly 
higher in ACR vs. no ACR patients both at day 5 (p=0.01 and p=0.001 
respectively) and at the day of liver biopsy (p=0.002 and p=0.001 respectively). 
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Figure 5.4 Expression of CD28 (A) and CD38 (B) on CD8+ T cells (B) from day 3 
until the day of ACR diagnosis. Patients were stratified according to the 
presence/absence of ACR. Expression of CD28 and CD38 were significantly 
higher in ACR vs. no ACR patients both at day 5 (p=0.03 and p=0.001 
respectively) and at the day of liver biopsy (p=0.02 and p=0.001 respectively). 
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Figure 5.6. Change over time of IL-17 levels at fixed intervals after liver 
transplantation. Patients with ACR presented significantly higher levels of IL-17 
on the day of protocol liver biopsy (p<0.001). 
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